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ABSTRACT
Though medical advances in the last century now allow us to forestall death, many 
patients suffer from significant symptoms as they battle severe disease.  Opioid medications 
are particularly effective when treating pain in these patients and infusion by the patient 
controlled analgesia (PCA) paradigm is commonly used in patients with severe disease.  
While PCA allows rapid titration yet individualized adjustment of opioid dose, it  involves 
complex, high-stakes decisions.  Unfortunately, clinicians complain that it is often difficult 
or impossible to find the data needed to make these decisions.  A relevant data display could 
support clinical decisions by providing real-time up-to-date clinical data at the point of care.
Literature synthesis and multiple modeling techniques were used to quantify the 
domain.  An inductive, qualitative approach, including graphical mapping techniques, was 
used to build a foundational domain information model which was subsequently validated 
using a survey of domain experts.  A gap analysis was performed, mapping concepts from 
the information model to the emerging HL7 FHIR standard.
Modeling revealed a complex workflow, highlighted the bottleneck in information 
flow to providers at the point of care, and supported the premise that a relevant data display 
would be beneficial.  The gap analysis showed that currently existing FHIR resources are 
capable of representing all relevant concepts from the domain information model needed for
decision making in this complex use-case.  Potential problems with FHIR implementation 
were identified and recommendations to address these are presented.
“We must all die. But that I can save him from days of torture, that is what I feel as 
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Despite tremendous medical advances over the last century, many patients with 
serious, life-threatening illnesses experience significant untreated pain as a consequence of 
disease or disease treatment.  The clinical specialty of Palliative Care emerged to meet this 
need, focusing on management of complex and difficult symptoms, including severe and 
intractable pain, in patients with serious and life-limiting illnesses.  Over the last 20 years, 
numerous approaches have been developed to combat pain in these patients.  One particular 
modality shows much promise: Patient Controlled Analgesia (PCA).  Originally developed 
to manage post-operative pain, PCA has been applied to pain management for very sick and 
terminal patients.  A striking advantage of PCA is that it involves patients in their care, 
allowing them to titrate their pain relief to what they feel is an adequate balance of analgesia
versus medication side effects.  At times the patient may prefer more analgesia despite side 
effects such as sedation; at other times he or she may choose less analgesia.  Thus PCA 
management is a real-world example of patient-centered medical care.
Because the modality allows rapid titration of opioid dose to the level the patient 
considers comfortable, parenteral opioid infusion administered by a PCA pump has become 
a commonly utilized modality in palliative settings.  Rapid titration of opioid infusions is a 
complex task, however, and requires an accurate and comprehensive understanding of 
numerous clinical factors.  Complicating this situation, Palliative Medicine specialists often 
2work as consultants, and it is not unusual for Palliative Medicine providers to manage as 
many as a half dozen PCAs on any given day with multiple providers involved in the care 
for each patient over the course of treatment. Therefore, managing and communicating 
information germane to PCA management is a critical element in the patient’s care.
Despite advances in electronic health records, the information needed to titrate and 
manage opioid infusions can be difficult to locate and aggregate in a meaningful way. There 
is little or no literature evaluating the adequacy and quality of data, with respect to 
managing PCAs, available to clinicians at the point of care.  Anecdotally, however, 
clinicians complain that they lack adequate data to make optimal titration decisions.
Automating the aggregation and presentation of relevant information holds the 
potential to address the problem of missing or difficult- to-locate information.   An emerging
HL7 standard, Fast Healthcare Interoperability Resources (FHIR, pronounced “Fire”), may 
be able to facilitate development of such a data aggregation tool.  FHIR is intended to 
provide a granular, modular way to exchange data, with less overhead than traditional HL7 
implementations.  It is intended to address real clinical needs and is designed for flexible 
custom workflows, web based APIs, mobile applications (apps), cloud computing, and 
medical device integration.1  The potential of FHIR to support such emerging technologies 
has been widely embraced, but as a newly emerging standard the actual extent to which it 
will succeed in these endeavors remains to be demonstrated.
1.2 Purpose and Aims
Clinical decision making in the management of opioid PCA infusions for palliative 
patients is a complex task.  Clinicians are challenged by lack of information on which to 
base decisions, and difficulty locating the information when it does exist.  The purpose of 
this research was to examine the feasibility of using a standards-based informatics 
3approach to manage information relevant to the use-case of managing opioid infusions 
in palliative settings.  The aims were:
1. To understand the information needs and data requirements informing decision 
making in palliative care PCA management through:
a. Development of an information model based on in-depth analysis of the 
use case.
b. Validation of the information model through formal expert review.
2. To examine the potential feasibility of using the emerging FHIR standard for the 
specialized use case of palliative care PCA management.  A gap analysis was 
conducted by mapping model elements to FHIR resources.
1.3 Significance
Despite the anecdotal reports of clinicians, who claim that they lack information 
needed to manage PCAs, we could find no literature evaluating the adequacy or quality of 
information available to clinicians at the point of care in this use case.  The information 
required to make decisions regarding opioid titration may exist within electronic health 
record (EHR) systems, but the mere existence of information in the EHR is irrelevant if it is 
not available when and where needed.  If needed information is present but scattered 
throughout the EHR, buried amongst thousands of other pieces of data, it is effectively 
absent as the effort required to retrieve it exceeds that which a clinician can or will 
expend.  An automated system could 8provide an ideal solution to this problem, as such a 
system could find data quickly and efficiently, aggregate that data into useful information, 
then display it in an easily assimilated format for use in decision making.
Automating the aggregation and presentation of relevant information holds the
 potential to improve PCA management for palliative care in two key ways.  First, such a 
4system would reduce the cognitive burden on clinicians, allowing them to focus on 
management decisions rather than expend considerable time and effort searching for  
information.  Second, such a system would supply a more consistent, complete, and accurate
set of data on which to base management decisions.  By reducing cognitive load and 
providing a more complete and accurate set of information that is presented in a uniform 
way at the point of decision-making, one could expect a reduction in human errors and in 
turn improved patient outcomes and safety.
1.4 Innovation
Automated systems to locate and aggregate data have been successfully applied to 
such tasks as trending labs and clinical data, providing a level of decision support through 
data presentation.2  However, very little if any decision support appears to have been 
developed for more subjective symptom phenomena, particularly the palliative care subject 
area, despite pain being a nearly universal phenomenon.  
FHIR, an emerging HL7 standard intended to support rapid development of mobile 
apps and modules that can enhance EHR functionality, is currently of high interest in the 
informatics community.  This project informs the design of an infrastructure upon which an 
EHR module providing decision support for management of opioid titrations could be built. 
The obvious first step would be a visualization tool, but the study also paves the way for 
development of a more elaborate, active clinical decision support system (CDSS) that could 
provide suggestions to providers in real-time at the point of decision making.  The benefit 
extends beyond this one use case; if FHIR is found to be robust enough to meet this 
challenge, it suggests the standard can be successfully applied to other similarly complex 
subject areas in clinical care.
51.5 Organization of This Manuscript
The subsequent chapters of this manuscript are organized as follows.  First, a 
literature review regarding palliative medicine, pain management, and the information 
management challenge provides background information and context for the study.  The 
three subsequent chapters describe: foundational work and targeted literature summary to 
understand the information needs within the clinical domain,  Aim 1 (methods, results, and 
discussion), and Aim 2 (methods, results, and discussion).  Finally, a concluding chapter 
discusses and summarizes the work.
CHAPTER 2
THE CLINICAL CONTEXT
Examination of the clinical context begins with an overview of the development of 
palliative care as a discipline and a philosophy of care.  Literature regarding late-life pain 
and management of pain crises, including patient controlled analgesia (PCA) and opioid 
medications, further elucidate the clinical issue that is the focus of the research use case.  
Finally, the information management challenge is described.
2.1 Historical Introduction
In the early part of last century, amazing advances in anesthesia, surgery, and 
antimicrobial therapy paved the way for a revolution in medical care.3,4  In the latter half of 
the century, amazing technological advances gave birth to the modern ICU (intensive care 
unit) with various modes of life support that further revolutionized medicine.5–7  This 
revolution in medicine had a profound impact on society, as the life expectancy drastically 
increased over this time.6   As one after another dreaded killers was conquered by medical 
science, the last pages of the lives of Americans became a very different story.  We no longer
died from rapidly fatal conditions, such as infection and trauma, but rather fell victim to 
slow, insidious killers like chronic diseases of the heart, kidneys and lungs, and cancers.4,8,9  
Before this great revolution, the work of physicians was to “care” for the sick and dying, but
after this revolutionary change, the focus of western medicine had become to “cure” 
disease.4,6,9–11  Despite this new goal, all patients eventually die.  The change, however was 
7that death now often followed a prolonged battle with disease, and patients often spent many
of their last days in hospitals or nursing facilities receiving intensive treatments, supported 
by various machines.10–19  This shift in focus from care to cure left much suffering 
unaddressed, while at the same time modern treatments often increased the suffering which 
patients endured as they lived out the ends of their lives.17(pp14-30),19–23
2.2 Palliative Care
2.2.1 Definition of Palliative Care
Recognizing that the suffering of patients was often overlooked by “modern” 
medicine, in the mid 1900's a few pioneers began to champion the application of medical 
science and technology blended with a human approach to provide relief to those suffering 
at the close of their lives.24,25  Their work and research lead to the modern movement of 
palliative care.  The concept of palliative care has evolved over the last half century, but the 
emphasis on relief of suffering has remained.  The World Health Organization's (WHO) 
definition of Palliative Care states:
Palliative care is an approach that improves the quality of life of patients and 
their families facing the problem [sic] associated with life-threatening illness, 
through the prevention and relief of suffering by means of early identification 
and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual.26
The National Consensus Project for Quality Palliative Care (NCP) describes 
palliative care as both a philosophy of care and a system of care delivery.  It is critical to 
understand that the term “palliative care” can represent these two distinct concepts – a 
philosophy of care and a system of care delivery.  This second concept, palliative care as a 
structured system of care delivery, is perhaps best illustrated by the multi-disciplinary team 
approach to delivering care.  Hospice care, an inpatient consultative palliative care team, 
and outpatient palliative care teams in an oncology clinic all provide examples of the highly 
8structured systems for delivering care as described by the NCP.  These systems of delivery 
are composed of multiple elements including various professionals, dedicated locations, and 
unique financing models, which are bound together into a functioning care-delivery system 
by associated specialized processes.  These systems of care delivery are very visible to 
clinicians, patients, and families, so it is common to hear people say “they have called in 
palliative care” or “we moved him to palliative care,” equating palliative care with these 
concrete parts of the system of care delivery.  While this concept of palliative care is more 
visible, it is the less visible concept from the NCP definition, of palliative care as a 
philosophy, which is integral to this work.
A philosophy of care is a paradigm or approach to caring for patients, “a framework 
of care goals and values to help you make the best choices.”27  In contrast to a system of care
that describe the mechanisms by which care is rendered, a philosophy of care drives what 
should be done and how.28,29  A philosophy of care can direct either the entirety of a patient's 
care, or can be influential over just one narrow segment of the care.  In the latter case it must
integrate with other philosophies of care.  The full NCP definition of palliative care is:
The goal of palliative care is to prevent and relieve suffering and to support the
best possible quality of life for patients and their families, regardless of the 
stage of the disease or the need for other therapies. Palliative care is both a 
philosophy of care and an organized, highly structured system for delivering 
care. Palliative care expands traditional disease-model medical treatments to 
include the goals of enhancing quality of life for patient and family, optimizing
function, helping with decision making, and providing opportunities for 
personal growth.  As such, it can be delivered concurrently with life-
prolonging care or as the main focus of care.30(p6)
The first phrase, “the goal of palliative care is to prevent and relieve suffering,” is an 
excellent yet concise statement of the palliative philosophy.   While these goals are simple 
and certainly not unique to palliative care, they form the core of palliative care as a 
philosophy.  Similar to the WHO definition of Palliative Care, this definition relies heavily 
on the idea of improving or maximizing quality of life.  In the palliative philosophy of care, 
9suffering is more than physical pain.  Dame Cicely Saunders, one of the early pioneers of 
Palliative Medicine, was one of the first physicians to weave this broad definition of 
suffering into her work.  In describing her role as a palliative physician, she describes 
suffering as a multifactorial and unique experience, intrinsic to an individual patient.  She 
stated the physician's role is to address
things that can add up to a general state of misery as a disease in itself … a 
complex of physical, emotional, social, and spiritual elements. The whole 
experience for a patient includes anxiety, depression, and fear; concern for the 
family who will become bereaved; and often a need to find some meaning in 
the situation, some deeper reality in which to trust.31(p1600) 
The Canadian Palliative Care Association likewise took a broad view of suffering while 
clearly focusing on the individual when they defined palliative care as 
a philosophy of care that provides a combination of active and compassionate 
therapies intended to comfort and support patients and families who are living 
with a life-threatening illness, being sensitive and respectful of their religious, 
cultural, and personal beliefs, values, and traditions.32(p342)
The goals of palliative care as a philosophy of care, then, are based on a broad definition of 
suffering with a distinct focus on the individual patient.
2.2.2 Scope of Palliative Care
While considerable confusion exists over what palliative care is – a system of care 
and a philosophy of care – the scope of palliative care is often even more misunderstood.  
Perhaps some of this confusion results from observing the highly structured system of care 
delivery and not recognizing, appreciating, or understanding the less visible philosophy of 
care that underlies that system of delivery.  Many mistakenly believe that palliative care 
should be reserved for those in the last few hours or days of life, in keeping with a very 
restricted definition of a “terminal” condition.  Others wrongly equate palliative care with 
hospice care which, in the United States, is defined by the Medicare Hospice Benefit, which 
requires that a patient no longer be seeking curative treatment.33–36  The result is that many 
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believe palliative care to be a distinct and separate form of care, incompatible and 
incongruent with curative treatments.
This narrow view of the scope of palliative care is at odds with how nearly every 
palliative care organization and those working in the field view the discipline.33,37–41  The 
WHO definition of palliative care lists a series of attributes of palliative care, including:
[Palliative care] is applicable early in the course of illness, in conjunction with 
other therapies that are intended to prolong life, such as chemotherapy or 
radiation therapy, and includes those investigations needed to better understand
and manage distressing clinical complications.26
Several statements in the first chapter of The National Quality Forum's (NQF) National 
Framework and Preferred Practices for Palliative and Hospice Care Quality provide a well-
stated scope of Palliative Care that provides further details:
Palliative care throughout the continuum of illness involves addressing 
physical, intellectual, emotional, social, and spiritual needs and facilitating 
patient autonomy, access to information, and choice.
Of particular importance, palliative care services are indicated across the entire
trajectory of a patient’s illness and its provision should not be restricted to the 
end-of-life phase.
Palliative care can be delivered concurrently with life-prolonging care or as the
main focus of care. … Palliative care continues from the time of diagnosis as 
long as the conditions and their treatments pose significant burdens until a 
reversal is achieved or death results.42(p vi)
Another NQF document, Policies and Tools for Hospice and Palliative Care Programs, 
similarly broadens the concept of end of life care stating,
“End-of-life care” is not bounded by a specific prognosis; rather, it involves 
the recognition of the irreversibility of a life-limiting medical condition(s) that 
will likely result in death.43(p16) 
As do these, most modern, widely-accepted definitions of palliative care describe it as 
appropriate for patients who are facing “life threatening” or  have “life-limiting” illnesses.  
This intentionally includes patients months or even years prior to death.  The time for 
palliative care begins long before the time immediately preceding death, those few hours to 
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days referred to as the “actively dying” stage of life.36,42,44,45  The key concept is that a 
palliative philosophy is appropriately applied to any patients facing life-limiting or life-
threatening diseases, irrespective of either how long they have yet to live or whether they 
are still actively being treated for their life-limiting condition.  The NQF explicitly 
denounces the idea of limiting palliative care based on a temporal prognosis, stating that 
palliative care may be appropriate “from the time of diagnosis.”
2.3  End of Life Pain
2.3.1  A Unique Problem Requiring a Unique Response
While suffering is a complex state and encompasses much more than physical 
symptoms, pain has been a particularly troubling symptom with which mankind has 
wrestled for centuries.46–49  In 1931 Albert Schweitzer summarized the situation in his day by
stating, “pain is a more terrible lord of mankind than even death itself.”50  It is not surprising
then, that pain was specifically targeted by early pioneers of palliative medicine.25,31,41,51–53  
Unfortunately, despite this work, Dr. Schweitzer's statement still remains true today; studies 
show that physical pain remains one of the most feared symptoms when patients think about
death and dying,5,54–59 and many patients still experience considerable pain toward the ends 
of their lives.21,57,60,61
Rather than endure pain, the goal is for seriously ill patients is to remain in a state of 
analgesia, the state of insensitivity to (or loss of the ability to feel) pain ,yet to 
simultaneously remain conscious.62  This goal of insensitivity to pain can be approached in 
many different ways and when compared to other philosophies of care, there are features of 
a palliative approach to managing pain that set it apart from the approaches of other 
disciplines.  It must be emphasized that treatment plans, protocols, practices, and approaches
appropriate in one setting may not be applicable to other settings.  What may be acceptable 
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and appropriate in a palliative setting may be completely inappropriate in other settings and 
vice versa.  One must, therefore, be cautious to apply the palliative approach to pain 
management only to appropriate patients.  Patients facing life-limiting illnesses differ in a 
number of important ways from patients in other settings; understanding those differences is
important to understanding the palliative approach to pain.
2.3.1.1 Unique Feature - Pain Intensity
Patients dealing with life-limiting illnesses face unique types of pain and pain 
syndromes.  As disease progresses,  in many cases the pain escalates as well.  Disease so 
profound that it threatens to overwhelm the patient despite all medical interventions often 
causes pain which increases to levels far more intense than the pain experienced from 
routine acute injuries or chronic pain syndromes.  This escalation all-too-frequently results 
in a situation referred to as a “pain crisis,” described in a 2008 JAMA article as a situation
 in which the patient reports severe, uncontrolled pain that is causing the 
patient, family, or both severe distress. The pain may be acute in onset or may 
have progressed gradually to an intolerable threshold (as Determined by the 
patient), but requires immediate intervention. National Comprehensive Cancer 
Network pain management guidelines identify a pain emergency as an event in
which patients have severe pain (a numerical estimate of at least 7 on a 10-
point scale) that requires rapid opioid titration to provide analgesia.  
[emphasis mine] 63(p1458) 
The same articles goes on to state:
There are no epidemiological data to suggest how commonly pain crises occur.
Our own experience at Memorial Sloan-Kettering Cancer Center suggests that 
of about 120 inpatient consultations a month, our Pain and Palliative Care 
Service is called for what is identified as a pain crisis by the referring 
physician as frequently as 20 to 30 times a month.63(p1458) 
Typical estimates of terminal patients experiencing significant pain are between 36 and 
75%,64 with a recent meta-analysis using stringent criteria suggesting around 65%.65  One 
study of patients with cancer found that 89% of them experienced moderate to severe pain 
with over 50% having moderate to severe pain at least “often” over the course of their 
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illness.66  Any regimen, then, needs to be able to cover a wide range of pain, from minor 
every-day aches and pain to the most severe and excruciating pains
2.3.1.2 Unique Feature - Pain Fluctuation
In addition to the severe nature of pain experienced by palliative patients, the types 
of pain caused by end-stage or terminal disease typically varies in intensity over the course 
of the disease.67  Disease progression can lead to steady increases over time or pain may 
quickly increase to crisis level in a short period.  Palliative patients often have variations in 
the short-term, such as over a day.  Sometimes these fluctuations are caused by certain 
activities throughout the day (such as changing position), but fluctuations in pain intensity 
may appear to occur randomly.  As such, palliative patients need a regimen capable of 
providing a steady level of analgesia to cover their “baseline” pain but also able to provide 
temporary increases in analgesic effect to cover  short-term “breakthrough” pain.68–70  
Developing a regimen that provides analgesia across a wide range of intensities, yet one that
is flexible enough to adapt quickly to rapid changes in pain intensity, is often challenging.
2.3.1.3 Unique Feature – Life Expectancy
Due to their life-limiting illnesses, patients in palliative contexts obviously have a 
shorter life expectancy than patients in other contexts.  As such, long-term side effects and 
long-term risks associated with certain medications or pain regimens are of lesser concern to
these patients.  More importantly, for patients with a short prognosis there is a sense of 
urgency to relieve their pain quickly so they can make the most of what time they have left.  
This concern applies especially to patients in acute pain, such as those suffering from a pain 
crisis.  The faster medication can be safely titrated, the better: speed is of the essence.  In 
fact, a longstanding metric for hospice is whether pain relief is achieved within 48 hours or 
less of onset (or admission to hospice);71,72 this is becoming a metric for palliative care 
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services as well.73   Methods of pain relief employed in palliative settings, then, must have 
both a rapid onset and the ability to be rapidly titrated in order to maximize the amount of 
“good” time the patient has.
2.3.1.4 Unique Feature – Physical Limitations
Given their severity, life-threatening diseases often impose significant physical 
limitations.  As a result, many patients are either homebound or require great effort to leave 
their homes.  Frequent travel to clinics or hospitals can pose severe hardship, adding to the 
patients' suffering.  Even within their homes, progressive physical limitation makes it 
important to keep treatment regimens simple and limited to what can be carried out with a 
minimum of effort.  As serious disease evolves it is common to have progressive organ 
dysfunction, such as liver or kidney failure.  This makes medication regimens with complex 
pharmacokinetics and pharmacodynamics difficult to manage and prone to failure due to 
side effects, adverse reactions, or medication interactions.  The combination of advancing 
disease, weakness, and organ dysfunction further makes patients poor candidates for 
procedural or surgical intervention for pain.
2.3.1.5 Unique Feature – Psychosocial Factors
An important, yet often overlooked, factor in the care of patients facing life-limiting 
illnesses is the impact the disease has on their psychosocial situation.  Such illness creates 
multiple psycho-social barriers for the patient.  Seriously ill patients lose control of much in 
their lives and face incomprehensible losses; understandably this often leads to severe 
emotional distress and an emotionally fragile state.  Anything that can be done to give 
suffering patients a sense of empowerment can be immensely beneficial.63  Involving the 
patient as much as possible, including setting goals of analgesia and in decisions about 
timing and amount of doses, can be extremely empowering to patients.74  In addition to the 
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impairment caused by emotional distress on patients and caregivers, dementia and delirium 
in patients and caregivers, even if mild, significantly impact the ability to comply with 
analgesia regimens.  Complex regimens are not an option; the regimen must be simple and 
straightforward.  Perhaps most importantly, though, many of these patients are on a fixed 
income with extravagant medical expenses, so simple, highly effective, yet low cost 
regimens are needed.
2.4 Opioid Medications for Palliative Pain Management
So, then, what is needed is a fast-acting and rapidly titratable means of providing 
analgesia over a wide range of doses that can be self-administered easily by the patient with 
minimal physical and mental effort, can be used in the case of physical deterioration and 
organ failure, and is inexpensive.  While this is a tall set of orders, one of the oldest classes 
of medications, opioids, holds the promise to fulfill many of these demands.
2.4.1 History of Opioid Use
Though the opium poppy has been used medicinally for the last 30,000 years,75 a 
turning point occurred in the 1800s when advances in chemistry allowed purification of 
potent opioids on a large scale.  Thomas Sydenham, a 17th-Century English physician, called
laudanum,  made of sherry, opium, saffron, and cloves, “the most valuable drug in the 
world.”75  Given such acclaim and availability, use of opioids became widespread and by the
turn of the century problems of overuse were apparent.  In 1914 the U.S. government 
stepped in to deal with the problem, enacting the Harrison Act,76 and suddenly this 
previously widely used class of medication became something feared, both by the public 
and practitioners.75,77  Opioids became associated with stereotypical images of “street 
addicts” and their use was quickly confined to the “periphery of society.”75,76  By the mid 
1900s, the prevailing mindset in the U.S. was that opioids should be used as a modality of 
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“last resort,” one reserved only for those “who were clearly dying.”53  Coupled with the rise 
of suffering at the end of life, this reluctance to use such an effective medication needlessly 
perpetuated much pain and suffering.  In 1986, in response to increasing concern over 
unrelieved pain, the WHO established an “analgesic ladder” to guide use of pain 
medications.78  This model was originally designed for use in treating cancer pain78–80 but 
became a de facto standard for management of many types of pain.80–82  While the WHO 
ladder improved the treatment of pain in many settings by increasing appropriate use of 
opioids,78,80 considerable fear and stigma still surround opioid use today, even for patients 
nearing life's end.75,83–86
2.4.2  Concerns about Opioid Use
Though opioids must be managed carefully, as there are dangers in both their short 
and long term use, the risks are no reason to avoid this highly effective class of medications 
in palliative patients.  There are certainly significant ill effects that develop over months to 
years of opioid use, but these are rarely an issue in palliative settings, as patients either are 
not expected to have a prognosis long enough to realize those side effects or the nature of 
the disease is so severe that compared to the suffering, the side effects, are negligible.87  The 
more immediate risks posed by opioids, however, are  important to consider and manage 
appropriately.88–90  One common concern is that opioids are potentially habit-forming; 
another is that if not used carefully, opioids can be dangerous, even deadly.
Opioids do induce chemical dependence and they are frequently abused.  However, it
is well established that the natural chemical dependence that accompanies repeated use of 
opioids over time does not correlate with increased levels of abuse.91  In patients in palliative
and hospice settings where opioids are used liberally to treat pain, the incidence of 
misuse/abuse of opioids has been found to be no greater than the rate of abuse seen in the 
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general public.31,92–95  Overall there has not been evidence linking increased rates of 
addiction to appropriate medical use of opioids in individuals who otherwise were not 
predisposed to (or have previously had) problems with addiction.84,92,96,97  It is vitally 
important, however, to keep in mind that this statement is predicated on the appropriate use 
of opioid medications.  The use of analgesic medications for any purpose other than relief of
physical symptoms (i.e. pain or dyspnea) is misuse; use of opioids to numb emotional pain 
(so called “chemical coping”) or for their euphoric properties (to get “high”) is misuse and 
indicates heightened risk of escalating abuse or possible later addiction.  If prescribers do 
not police the use of opioids appropriately and allow use of higher doses than needed to 
achieve analgesia, or if they allow or enable indiscriminate use of opioids, the risks of abuse
and addiction do likely increase considerably.   The importance of prescribers managing 
opioid regimens with vigilance cannot be over-emphasized.  This author has personally 
witnessed significant problems develop on many occasions, sometimes with devastating 
results, when prescribers have failed to keep the purpose of opioid regimens focused on 
analgesia.  Merely being in a palliative setting provides no protection against the dangers of 
improper use of opioids.98,99
The second concern, that opioids are “dangerous” medications, is a concern 
frequently taken out of proportion.  Many classes of medication and many procedures used 
in routine daily medical care in clinics, hospitals, and patients' homes involve risk.  What 
protects patients from harm in such cases is the skill and dedication of the provider 
managing the regimen or performing the procedure.67,100–102  Though not the only danger, the 
most feared short-term complications of rapid escalation are sedation and respiratory 
depression with either potentially even leading to death.103–105  With skill developed through 
appropriate training and experience combined with the appropriate level of attention 
dedicated to the case, even complex rapid titrations of opioids to exceptionally high doses 
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can be managed safely.97,106–111
2.4.3 Properties of Opioids That Are Advantageous
for Palliative Settings
Despite the concern with opioids, they have a number of unique properties that allow
them to effectively meet the needs for an analgesic in palliative settings.  Opioids have a 
very wide therapeutic range, from very small to massive doses.  In fact, one of the key 
attributes of opioids is that many opioids (the mu-agonists) have no therapeutic ceiling.  
This means if any current dose is ineffective in a particular individual, in the absence of 
precluding opioid-induced side effects, it is safe to raise the dose irrespective of how high 
that dose is.17(p317),90,102,106,107,112–114,115(p81)  Opioids also have a relatively rapid onset.  While 
typical oral forms of opioids not engineered to be long-acting or slow-release reach their full
analgesic potency within an hour, when given by the parenteral route (intravenous or 
subcutaneous injection), most opioids begin taking effect within a matter of minutes and 
reach full potency within a half an hour or less.17,67,114,116  This rapid onset allows titration to 
large doses within a matter of hours.63,117–119  While each opioid has a unique 
pharmacokinetic profile, traditional opioids (i.e.  morphine, hydromorphone, oxycodone) 
have half-lives of about 2-4 hours, allowing them to be titrated down over a few hours, 
should that be needed.  Most opioids also have relatively benign side effects and metabolite 
profiles and, when managed by skilled professionals, can be successfully used despite 
declining health and organ failure.102,114,120–122  Even in the last hours or days of life as the 
body shuts down, opioids can safely provide analgesia through the point of death.  Opioids 
are also relatively easy to administer in a patient's own home either by oral dosing or an 
infusion.  Long-acting oral forms of many opioids are available, allowing an entire day's 
worth of very potent analgesia to be simplified into one to three doses of scheduled oral 
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medication.  This allows even high dose infusions to be converted to oral regimens 
providing the same level of analgesia but involving only a few pills per day.  While there are
opioids that are quite expensive, many opioids have generic forms available, and overall 
opioids are arguably one of the least expensive classes of analgesics available.102,118,123–125
Opioids, then, are ideal analgesics for many patients in palliative settings.  While 
many palliative patients are served well by opioid regimens, each situation must be 
individually evaluated to determine the best analgesic strategy.  When rapid relief is 
required, such as in a pain crisis, parenteral infusions of opioids is often the method of 
choice to gain control of pain quickly in palliative patients.  However, infusions require 
needles, lines, and pumps which are cumbersome, have more potential failure points, and 
impair mobility.126  For these reasons, when rapid titration is not required, it is routine to use 
oral opioid regimens, which provide the same level of analgesia but are simpler, less 
intrusive, and cheaper for the patient.80  The common fluctuations in pain intensity between 
extremes seen in palliative patients, however,  necessitates a very adaptable regimen for 
palliative patients, and it is not uncommon for a patient to be switched back and forth 
between parenteral and oral dosing, as the patient's pain requires.  These conversions and 
rapid titrations are very complex and require considerable skill and expertise to accomplish 
safely.63,108,109,111,127–130
2.4.4  Subjective and Individual Nature of Pain
Physical pain is a subjective experience, an aggregated mental perception that results
from, and is shaped by, a multitude of sensory perceptions and internal processing.102,131–133  
While an analysis of pain as a phenomenon is beyond the scope of this work, that it is 
subjective has a direct bearing on this work.  A tenet of palliative care is that pain is a 
perception truly knowable only to the patient who is experiencing it; pain is what the patient
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says it is.4(p329),17(p301),107,131
Many physical factors affecting both a patient's perception of pain and their 
responsiveness to opioids vary from one individual to the next.  Opioid binding receptor 
profiles vary from one individual to the next, as do metabolism and clearance 
mechanisms.67,114,134–136  Additionally, the pain transmission pathways and integration centers 
in the body are very plastic and adapt to intrinsic and extrinsic events, varying in response to
many factors.  The phenomenon of “wind up” (when repeated or continuous painful stimuli 
over time lead to higher and higher perceived levels of pain), and the development of 
tolerance (when the same dose of opioid becomes less effective with continued repeated 
use), are examples.  Both of these factors vary significantly between different individuals.134
Equally important in the perception of pain are a host of psychological and 
emotional factors including mood, perception of disease progression, and social 
situation.67,88,134,137  Because of this, two individuals with physiologically similar events may 
perceive vastly different levels of “pain.”  It is only expected, then, that the amount of 
medication required to achieve “analgesia” will vary between individuals.97,134,138,139  Further, 
even the same patient may have markedly different analgesic needs at different times as any 
of the factors involved in creating the experience of pain change.97  Years of research have 
failed to discover overall “optimal” doses of various opioids, instead showing that 
individuals have very different opioid requirements across a broad range of doses, 
reinforcing the idea that pain cannot be approached with boiler-plate regimens, but rather 
each episode must be approached individually.97,106,134,140,141
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2.4.5  An Answer to the Need for Individualized
Parenteral Opioid Regimens
The need for highly individualized pain regimens, especially when using opioid 
analgesia, has long been known.  Early pioneers of palliative medicine advocated involving 
patients in their pain management by ordering rather liberal doses titrated upwards, 
sometimes by patients themselves, until patients remained in a state of analgesia.52  
Involving patients in this way proved successful for adjusting analgesia to pain that evolved 
rather slowly or had a stable pattern of fluctuation, but for complex patients such as those 
requiring high doses or rapid titration, the system was cumbersome.  While use of parenteral
opioids leveraged rapidly acting medications, the process of a patient summoning an 
attendant and discussing the need for medication, followed by the multiple steps involved in 
an attendant checking orders, obtaining the medication, and then finally administering it, 
was anything but smooth, and often involved considerable delays.96,106  Though a patient 
could request a dose “as needed,” many factors beyond his or her control affected the timing
and dose of medication delivered leading to delays and inadequate analgesia.106,142  The 
patient provided input, but was not truly in control of the analgesia regimen.142,143
With the advance of technology in the 1960's, a possible solution appeared when 
several anesthesiologists  independently began experimenting with the idea of post-
operative patients controlling their own analgesia using automated pumps.  Philip Sechzer is
often credited as the first to develop the idea in early 1965 when he had patients directly 
signal a device which, in response, provided them with doses of medication.144,145  In 1968 
Sechzer published preliminary findings,146 and in 1970 he published a report of his “Patient-
controlled analgesic-demand system.”145  Other pioneering anesthesiologists of that time 
were experimenting with similar systems, including William Forrest in Palo Alto, 
California,144,147,148 Michael Keeri-Szanto in London, Ontario,144,149–151 and J.S. Scott in Leeds,
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United Kingdom.144,150  While Sechzer's main interest was in using this device for research, 
Keeri-Szanto continued to push the concept into the clinical realm,144,150 advocating its 
widespread use throughout the hospital.151  Eventually, the concept of patient-controlled 
analgesia (PCA) became a mainstream modality for pain control, and by the 1980s was used
frequently in post-operative settings.96,97,150–152  Though by strict definition, PCA is a 
paradigm, the term has become synonymous with IV infusion pumps having some triggering
device that a patient uses to signal the pump to deliver a dose of medication.97  As 
technology evolved, pump sophistication grew such that multiple parameters regarding 
doses and timing could be set, pumps delivered continuous infusions along with the demand 
doses, and parameters such as requested doses, delivered doses, and total medication 
delivered were recorded.  By 1990, the use of the PCA paradigm had started to make its way
into oncology practice,148,153–158 and by the mid 2000s opioid PCA use was firmly entrenched 
in palliative medicine.126,159,160
This paradigm shift truly allowed the patient, as opposed to the physician, nurses, or 
family, to be in control of the amount of analgesic received.  While general constraints are 
put in place by the prescriber, within those bounds the patient determines when and how 
many doses of analgesia they receive.  This accomplishes several goals.  First, it can 
empower the patient, giving them some sense of control.161  Second, it aids in the rapid 
titration of a parenteral opioid regimen.159,160,162  By observing the number of attempts a 
patient makes of the infusion pump and correlating that with their pain scores, the prescriber
gains an understanding of the effects of increasing doses.  As the clinician increases either 
the basal infusion rate or the size of the bolus doses delivered in response to patient requests,
eventually the patient will begin to space out their demands for bolus doses and rate their 
pain lower.  This indicates one is approaching blood concentrations of opioid consistent with
a state of analgesia.97  Thirdly, the PCA paradigm incorporates an important safeguard 
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against possible opioid overdose.  The great concern in opioid titration is an overdose 
resulting in death, usually caused by hypoxia from respiratory depression.  If managed 
appropriately by a skilled provider knowledgeable about opioid use and medication kinetics,
the regimen is structured such that before a patient reaches a point of respiratory depression,
they become somnolent and thus no longer able to request additional bolus doses.96  Without
further boluses, the opioid level will decrease (or at least cease to rise) and the blood opioid 
concentration should not reach levels that cause respiratory depression.67,163  Despite this 
theoretic safeguard, adverse events, and even fatalities, do occur.100,103,164–167  Even when 
performed by skilled, experienced, and attentive providers, managing opioid infusions by 
any method, including by PCA, is a complex processes, thus prone to error.
2.5  The Informatics Challenge
Because it meets many of the described needs in patients suffering from life-limiting 
illness, opioid infusion using a PCA paradigm has become widely accepted as the preferred 
modality to achieve rapid relief of pain in palliative settings.118,159,143  The process typically 
involves giving loading doses, rapid titration, a period of smaller adjustments to hone the 
level of analgesia, then, when analgesia is established, often a conversion to an oral 
regimen.168  Given the complexity and potential dangers involved in rapid dose escalation, 
PCA infusions require skilled providers to make frequent high-stakes decisions 
throughout the process.  They are therefore typically carried out under close supervision, 
usually in a hospital or other inpatient setting.142,164,165,169,170  To maintain the safety of the 
patient when using a PCA infusion, it is important that those managing the infusion have 
accurate and appropriate clinical information on which to base decisions.  Anecdotally, 
palliative experts complain they frequently do not have adequate data to make decisions in 
these complex situations.  This author has likewise often struggled with this lack of data 
24
over the course of the last ten years of his work as a palliative specialist.  In the past in 
settings dedicated to palliative care, such as a dedicated inpatient unit or a hospice, some of 
the needed data was available on large, paper flowsheets.  As EHRs have become 
increasingly common, paper flowsheets have been replaced by computers.  Data may be 
culled from these systems, but this is a process beset by many challenges.  In these best-case
scenarios, the data needed for decision making must be actively sought by looking to various
places in the EHR; it is rarely presented in a clear, concise, organized manner.  Before the 
provider can analyze and synthesize, he or she must spend considerable time searching and 
jotting down notes.  In other cases, such as general hospital wards, the ICU, or outside the 
hospital, data availability is even worse, and there are actual or functional data “holes” such 
that despite searching, data cannot be found.
One would assume that experts who are comfortable in managing these cases know 
what data they need and will actively seek it out despite challenges, as they reason through 
the process of clinical decision making.  It may be another story for providers managing 
opioid titrations who, due to insufficient training and experience, are not “experts.”   One 
can only speculate whether they will know specifically what information to look for and 
then search deeply enough to find it.  For either the expert or novice, having to search 
multiple locations throughout the record, even if the data are in predictable locations (which 
is rarely the case), creates a fractured and circuitous workflow.  Such inefficient, complex 
workflows increase the cognitive load and thus the potential for  errors.171–175
While the data required to make decisions regarding opioid titration may exist within
EHR systems, providers complain that they often cannot find or struggle to find the needed 
information.  Within an EHR, if specific fields for the information needed for decision-
making when managing opioid titrations are lacking, such capacity should be relatively 
straight-forward to add either at the local installation level or at the vendor level.  
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Presupposing that capacity to store needed data elements exists within the EHR but is not 
used, education and accountability regarding accurate and appropriate documentation could 
ensure necessary data are stored within the EHR.  However, none of this ensures availability
of necessary data to the clinician when making decisions.  If needed data is scattered 
throughout the EHR, buried amongst thousands of other pieces of data, the effort required to
retrieve it can exceed that which clinicians can or will expend.  The mere existence of 
information is not helpful if the provider is unable to access the information; in those cases  
it is as if the information does not exist.176–178  In situations where information is difficult to 
find or access, the data are effectively absent to the clinician, and it is likely that decisions 
will be made without use of all desirable information.179,180  For providers to make 
potentially high-stakes management decisions without adequate information presents at least
a barrier to high quality pain care ,even if it does not always result in errors and harm to 
patients.  
An automated system, in contrast, could be designed to find data quickly and 
efficiently, aggregate that data, then display it in a visual form that a human operator could 
easily assimilate and use in decision making.173,181–183  While there are exciting advances 
coming, such as the development of “smart pumps,” we could find no literature evaluating 
the adequacy or quality of data available to clinicians at the point of care, or methods or 
projects to improve on the perceived lack of data when managing PCAs.  This study was 
designed to partially address that knowledge gap.
CHAPTER 3
FOUNDATIONAL EXPLORATORY WORK
3.1 Initial Evaluation: Modeling
3.1.1 Information Transactions
When considering the clinical scenario of opioid infusion by PCA pump in palliative 
patients, and how to improve upon the potential problem of data availability, the first step 
was formally describing the involved information transactions.  This modeling exercise was 
carried out based on the author's nearly 10 years of experience managing PCAs as a 
specialist in palliative medicine, and with informal input from other specialty palliative 
providers.
Initial modeling efforts revealed a highly complex system of information flow for 
managing opioid PCA regimens in palliative settings.  This model of information flow may 
be seen in Figure 3.1.  To simplify and structure the model, a high-level model of 
information flow was created using BPMN techniques; it is shown in Figure 3.2.  This 
BPMN model was then used to create a general model of data flow in the health care system
as seem in Figure 3.3; the generalizability of this model was shown by its adaptation to the 
flow of patient preference information within the healthcare system and subsequent 
presentation as a poster at the AMIA 2013 annual convention.184
The model of information flow shown in Figure 3.2 describes three sources of 
information, indicated by dark/shaded areas.  First, the patient serves as an important 
primary source of information.  There are common and accepted ways to obtain data from 
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the patient: typically a health care worker questions and physically assesses the patient.  
When there is a  PCA infusion pump in use, the data it captures and stores becomes a second
valuable source of information, as shown by the shaded swim land labeled “PCA Pump” in 
Figure 3.2.  PCA pumps routinely keep an electronic record of many parameters including, 
for instance, doses given, doses requested, and interval total medication given.  Routine 
practice in clinical settings is that nursing staff interrogate the pump at periodic intervals, 
physically write down the information, and later reenter data into the EHR or paper chart.  
While many pumps have the capability of exporting the data they collect in a structured 
format, for instance, into an EHR, currently this functionality seems not to be utilized by 
institutions or EHR systems;185–188 no formal research, investigation, or reports could be 
found on actual application of this potential.  In addition to reducing workload on nursing 
staff, interfacing PCA pumps with EHRs could increase the amount and improve the quality 
of data available within the EHR.  Such interfaces should prove relatively straightforward to
create as the data in PCA pumps are discrete numeric and text-string data.  However, even if 
such interfaces do improve the quantity and quality of data available in the EHR, merely 
being in the EHR does not ensure data are accessible to providers.  The EHR, then, 
represents the third source of data in this model.  Data are repeatedly gathered from the 
patient and the PCA pump and entered into the EHR.  Other primary data, such as results 
from laboratory, radiographic, and other tests, as well as reports of various kinds, also find 
their way into the EHR.  Further, as healthcare providers document their findings, thoughts, 
and impressions, the volume of this “synthesized” information present in the EHR grows.  
This longitudinal record of both primary and synthesized data makes the EHR a valuable 
source of information.  
From the model (Figure 3.2)  it can be seen, however, that without the ability to 
move this information in real-time to the point of care when it is needed, the information 
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cannot have an impact on clinical care or outcomes.  The complaint of providers that they 
lack necessary information at the point of care appears consistent with the lack of a 
mechanism  to accomplish the identified “weak link” of movement between the EHR (or 
other clinical data store) and the provider at the point of care.  Given the complexity of the 
task of managing and titrating opioid infusions in palliative settings, this is concerning, as it 
is well established that increased complexity of a system increases the number of failure 
points and thereby increases the odds of failure.189–193   This finding affirmed that this is an 
area to which application of a CDSS that could efficiently aggregate and present data to a 
provider could provide significant benefit.
3.1.2  UML Modeling
To further evaluate the interactions of various individuals involved in the flow of 
PCA pump-related data, and to narrow the scope of the project to something feasible and 
realistic, several Unified Modeling Language (UML) diagrams were created.  UML 
(http://www.uml.org) is an international standard (specification) for how to model 
application structure, behavior, and architecture as well as workflow processes and data 
structure.  Figure 3.4 is a UML context diagram showing the key actors and systems at a 
high level.  Of interest were the interactions between the health care providers and EHR, as 
seen in the use case diagram in Figure 3.5, and more specifically, the individual who is 
managing the opioid PCA infusion, called “prescriber” in Figure 3.6.  While the prescriber 
interacts with the EHR in several ways, of particular interest is the retrieval and display of 
patient data pertinent to opioid PCA management decisions.
3.1.3 Visualization Prototyping
A fundamental question at this point was whether physicians would prefer a visual 
display of data aggregated by a CDSS to the current practice of navigating to various 
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locations in the EHR to extract the data themselves.  To informally evaluate this question, 
drawing on nearly a decade of managing complex opioid titrations, this author began to 
experiment with various ways to visualize data he felt important when managing complex 
opioid PCA regimens in palliative settings.  The results were the mock screen in Figure 3.7.  
This mock screen was informally shown to 4 other seasoned experts in palliative medicine 
at 2 other institutions; the informal response was overwhelmingly positive.  All providers 
said such a screen displaying this data in a visual format would be incredibly useful.  One 
provider insisted on keeping a copy of the mock screen for her records.  Though informal, 
this overwhelmingly positive response indicated that this type of display was not threatening
and might be a benefit to providers.
3.2  Targeted Literature Review
A literature search was performed to identify evidence-based methods and/ or 
guidelines for PCA management to be used as the basis of a CDSS.   As management of 
opioid PCAs is a task almost exclusively in the domain of health practitioners, PubMed was 
the database of choice.  Multiple approaches were used to generate search terms: key-word, 
text-title word, and MeSH (Medical Subject Heading) term searching.  MeSH terms are 
formal, hierarchically arranged subject headings developed by the NLM (National Library 
of Medicine) and applied by the NLM to published medical literature at the time of 
cataloging.  As MeSH terms are arranged in a tree-like structure based on increasing 
specificity, identifying terms that referred to opioid infusion, opioid analgesia, PCA, and 
other concepts of interest was accomplished by directly perusing the MeSH tree.  
Publications on the PCA paradigm are plentiful, with a few early articles in the 1960's, more
in the 1970's, and then a significant increase in publication in the 1980's and into the 1990's. 
In the body of literature amassed there was considerable research about the effectiveness of 
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opioid PCA, use and comparison of particular agents, and many other topics related to pain 
research and pharmacology.  However, neither primary research on how to manage and 
make decisions regarding titration of an opioid PCA regimen in clinical settings nor 
evidence-based guidelines for such management were found.  The closest artifact to such 
evidence was the National Comprehensive Cancer Network (NCCN) guidelines, which are 
an evidence-infused consensus statement from an expert panel.168  There is no shortage of 
expert opinion on how to manage a PCA expressed in the literature.  Interestingly,  
expressed expert opinions seemed to be consistent, frequently citing accepted practice as 
justification.  This suggested that as the PCA paradigm developed from the 1960's through 
the early 1980s, consensus regarding appropriate management of PCAs in clinical settings 
developed and became accepted practice before the PCA paradigm became a topic of intense
clinical research.   Understandably, as a PCA pump is a means of delivering an opioid 
regimen, it seems reasonable to apply many of the well accepted guidelines of opioid 
titration to this use case as well, but again, the basis for suggesting how a clinician should 
titrate opioids appears largely to be based on standard accepted practice rather than specific 
studies.  To deepen the search and in hopes of uncovering evidence-based foundations for 
the expert opinion so readily offered, the citations of many of the publications retrieved on 
PubMed searching were themselves retrieved and reviewed.  Again, little primary evidence 
to guide a clinician in making decisions regarding adjustment and titration of opioid PCA 
infusions could be found.  Other interesting observations from the body of literature 
retrieved showed that early research and publications through the 1980s were limited to the 
post-operative setting.  In the late 1980's and early 1990s articles began to appear discussing
and evaluating the application of the PCA paradigm to the setting of cancer and medical 
illness.  As they appear late in this time course, most articles on the topic of opioid PCA use 
in palliative settings tend to assume how to manage an opioid PCA is a-prior knowledge and
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that in general, some 'standard' practice is followed.
3.3 Exploration of Mechanisms to Represent Data
A technical infrastructure is required to support a relevant information display-based
CDSS, including a system to convey data from the storage location within the heath 
information system to the provider's display.  Certainly such a CDSS could be a native 
application within an EHR, in which case proprietary terminology bindings and data 
representation methods would suffice.  This would, however, tightly couple the CDS 
application to the single system to which it is native, likely limiting its use to only that 
single parent application, as well as making it difficult to use any outside data sources.  This 
is a well-known problem for which the informatics community has been seeking a solution 
for quite some time.194,195  Currently, there is considerable interest in modular design for 
EHR systems to enable more customization and wider re-use of innovative ideas and tools.  
Building CDS aids in a modular, EHR-agnostic fashion allows them to interface with 
multiple EHR platforms, achieving a much wider impact than if build on a single, 
proprietary system.  Critical to accomplishing this modular architecture is a standardized 
method to pass data between modules without losing clinical meaning.  Technical standards 
such as FTP and TCP/IP could easily transmit the data, but representation of transmitted 
data has yet to be standardized.  FHIR, an emerging standard from HL7, is intended to fill 
this gap, resulting in improved real-world clinical interoperability.  Basic design features of 
FHIR include flexibility and simplicity with a formal extension process.  Extension allows 
FHIR to accommodate clinical data falling outside of its native ability to represent data and 
information.
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3.4 Summary of Exploration
While it was already appreciated that managing an opioid PCA infusion is a complex
task, this initial modeling work revealed that the requisite information flow to support this 
task is complex in its own right and is heavily reliant on humans as the conduit of data, a 
situation which creates multiple potential failure points.    The obvious question was 
whether this deficiency could be addressed by a CDS application which would aggregate 
necessary data with the goal of displaying that data to clinicians in a simple, easily 
understandable manner.
The lack of a clear evidence-base to serve as a foundation for a CDS application 
posed the first challenge: determining what are the data needed.  As expert opinion seemed 
to consistently reference the same concepts, and as research articles based their protocols on 
similar assumptions about the same concepts, it seemed that there were common, 
underlying, guiding principles.  It was therefore hypothesized that an inductive approach 
might be used to quantify the data and information which seemed to underlie expert decision
making, and thus could provide the needed basis for the proposed theoretical CDS 
application.
The second challenge, identified directly from the modeling, was how to convey the 
needed information from an EHR or other health data store to the proposed relevant data 
display CDSS.  Preliminary exploration of the HL7 FHIR specification suggested it might 
provide a solution.  How well and how easily FHIR could be used to accomplish this task 
was felt to hold the potential to suggest how well it could be applied to other such domains.








































































































































































































































































































































































































The goal of Aim 1 was to develop a solid understanding of the information that 
providers use to make management decisions regarding opioid PCA infusion regimens for 
palliative patients.  As the ultimate goal was to develop a decision support tool, in keeping 
with traditional informatics practice, an information model was developed and used to 
accomplish this aim.  A tool that supports decision making by providing data at the point of 
care should not display all data, but rather should display the relevant data - data that are 
actually needed at that point in time.2,175,196,197  In keeping with that principle, the information
model was not developed to provide a comprehensive or exhaustive list of all data and 
information elements involved in management of an opioid PCA, but to reflect those 
typically and frequently used by practitioners managing opioid PCA regimens in palliative 
settings.
Aim 1 was accomplished in two phases.  In Phase 1 a systematic literature review 
and analysis was used to derive a list of concepts involved in decision making and 




4.2  Phase 1: Defining the Data and Information Elements
4.2.1 Methods
4.2.1.1 Design
Phase 1 began with a systematic literature review.  Graphical mapping techniques 
were then used to summarize, synthesize, and organize concepts from the literature.198,199  
From an initial free-form mind map that represented all instances of concepts identified in 
the literature, a concept map displaying the unique data and information elements was 
abstracted.  This concept map was then formalized into an information model.
4.2.1.2 Sampling
The sample for the systematic literature review included three distinct types of 
artifacts: published journal articles formed the core of the review, textbooks and guidebooks 
provided additional academic sources, and clinical protocols from several health institutions 
provided real-world practical data.  The sample sources are shown in Table 4.1 and a 
diagram showing the process is shown in Figure 4.1.
An initial search of journal articles was performed using the PubMed database.  As 
management of opioid regimens is limited to the domain of health care practitioners, 
PubMed was the only literature database used in initial searching.  To identify articles 
published from 1950 to the present, searches using simple text, key-word, and title-words 
were performed based on combinations of the terms “patient controlled analgesia,” “PCA,” 
“palliative,” and “palliative care.”  Articles of interest were those that discussed or described
the clinical use of opioid medications given by parenteral (intravenous or subcutaneous) 
infusion using a PCA paradigm.  Particular attention was paid to articles with a palliative 
focus, but as the PCA paradigm developed out of the anesthesia domain and post-operative 
setting, this was not a strict criterion lest foundational articles be missed.  The bibliographies
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of articles were reviewed and relevant works cited there, if not already present in the corpus 
of identified articles, were obtained.  This process was followed until results of searches 
began to show high overlap with articles already included in the corpus.  Finally, the abstract
or full text of the article was reviewed for relevance.
Well known, well respected, and oft quoted palliative texts and guidebooks were 
reviewed.  For these materials, sections dealing with either PCA use or opioid management 
were identified, extracted, and included in the corpus.  As opioid PCA regimens are a 
specialized type of opioid analgesia regimen, sections on opioid management were also 
included.
The last category of material included in the systematic review was clinical 
protocols.  Several healthcare institutions around the country were contacted with a request 
for protocols dealing with palliative use of opioid PCA regimens.  Interestingly, palliative 
experts at several institutions responded that they had no protocols in their institutions that 
they felt should be used as evidence in a project such as this.  As with the texts and 
guidebooks, sections of protocols related to opioid infusion management in general were 
included, as PCA regimens are a specialized subset of opioid regimens.
4.2.1.3  Data Collection Methods - Annotation
The protocol for annotation and the number of sources to be used was determined 
prior to beginning the review.  In this protocol, a single reviewer (this author) reviewed 
sources in electronic form, and tagged any mention of a data or information element 
associated with management, adjustment, or assessment of an opioid PCA regimen.  As 
typical of qualitative inquiry, this reviewing and tagging procedure continued until a state of 
saturation was reached.  We defined saturation for this project as when, after review of the 
initial set was complete, 3 or more consecutive new sources were reviewed but revealed no 
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new elements.  At the point this criterion was met, it was assumed all major concepts used 
for decision making in the domain had been identified and the set of tagged data elements 
was considered complete.
Tagging of sources, extraction of tagged data, manipulation of extracted data, and 
qualitative review of data was carried out electronically, so considerable document 
processing and manipulation was required.  A pipeline approach was used to facilitate data 
extraction and qualitative review by combining several different applications in series.  This 
pipeline is illustrated in Figure 4.2.
The first step in the process was to obtain the full text of each source.  For sources 
such as textbooks, handbooks and protocols that were available only as a paper copy, 
sections identified as relevant to the scope of this project were scanned to create an 
electronic file.  “ScanTailor,”200 a free document processing application, was used to process 
initial scanned images.  With this application, image files can be combined, cleaned, 
aligned, straightened, cropped, then saved as high-contrast, monochrome, multi-page PDF 
files.  For documents obtained in electronic format other than PDF, various tools were used 
to convert them to PDF format, including “LibreOffice Writer,”201 the “Ghostscript”202 and 
“ImageMagick”203 command line tools for Linux, and others.   In order to be processed in 
the pipeline, all PDF files needed to have a text layer; files created from scans or other 
images lack this layer.  For any PDF file that did not already have a text layer consisting of 
the full-text of the article, one was created using the optical character recognition (OCR) 
feature of the application “PDF-Xchange Viewer.”204  Once all files were available in the 
PDF format with the required text layer, they were ready for annotation.
Annotation was carried out using an Android tablet (an Acer a200).  Files to be 
annotated were transferred to the tablet by FTP over WiFi (using an FTP server called 
“FTPServer”205 on the tablet and the FTP client “Filezilla”206 on the PC) or using an 
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application called “Dropsync.”207  Dropsync allows true, bi-directional synchronization of 
files between specified directories on any PC and an Android tablet device via a Dropbox208 
account.
Once transferred to the tablet, the reviewer opened and read each source with one of 
two applications, “Repligo Reader”209 or “ezPDF Reader.”210  When any mention of data or 
information regarding adjustment or management of a PCA regimen was identified, he 
annotated it with the high-light annotation tool of the PDF reader.   When annotation of each
source was completed, the source was transferred  to the Dropbox account or PC to await 
the extraction of tagged elements.
The way in which Repligo Reader and ezPDF Reader create annotations in the PDF 
file is a critical feature that makes possible the later techniques in this pipeline.  Both 
applications can create highlight annotations by copying the highlighted text to a secondary 
location in the PDF text layer where it is stored as a discrete annotation object.
4.2.1.4  Analysis – Mind Mapping
The open source application Docear211 was used to extract and analyze the 
annotations to produce a mind map.  A mind map is a flexible, free-form approach to 
diagrammatically representing concepts and relationships where concepts are represented as 
nodes arranged into a tree structure with relationship links and other metadata represented 
visually.212    Docear is self-described as an “Academic Literature Suite.”  It combines fairly 
robust mind-mapping capabilities with features of typical reference managers.  Docear can 
extract annotations from a PDF file by first creating a node to represent the parent PDF file 
then creating a child node for each annotation object stored in the PDF text layer.  Each 
node's label is set to whatever text was saved in that annotation object by the PDF reader 
when the annotation was created.  Once extracted, nodes may be moved, grouped, sorted, 
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and enriched by the addition of tags, graphical icons or other metadata.  Each node extracted
by Docear is individually tagged with information referencing the annotation's location in 
the source PDF.  This allows a user to search for, sort, and count nodes based on their source
document as well as to open the source PDF to the precise location of the annotation in the 
document even after considerable manipulation to the structure of the mind map.
After annotations from a source were imported into an initial mind map, simple 
drag-and-drop functionality was used to move, organize, and group elements into categories.
Within each category, nodes were organized into a hierarchical structure.  For example, if 
“GI side effects” was identified in one source and “nausea” was identified in another, a 
category of “side effects” could be created with the node “GI side effect” as a child and then
the “nausea” node placed as a child under “GI side effect.”   Once all annotations from the 
initial set of sources had been organized, saturation was assessed.
To assess saturation, 4 additional protocols were reviewed, annotated, and imported 
into the mind map, using the process previously described.  Each element in the 4 protocols 
was successfully mapped to an existing concept and no new elements were identified.  This 
met the pre-established definition of saturation.  Additional journal articles were then 
reviewed, annotated, and imported to the mind map.  In the first article reviewed to assess 
saturation, a concept not currently represented on the map was identified.  While this 
element was a new concept, it did fit into an existing category.  After this, 4 additional 
articles were sequentially reviewed, annotated, and annotations were imported into the mind
map.  All elements identified in those articles mapped to concepts currently represented in 
the mind map with no new elements identified.  This fulfilled the prespecified definition of 
saturation.  The list of protocols and articles used to assess saturation is shown in Table 4.2.
Having reached a state of saturation, this mind map was considered complete.  It 
represented evidence-based data and information elements involved in managing an opioid 
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PCA organized into a hierarchical model.  Each node corresponded to one mention of a data 
or information element used in making decisions when managing an opioid PCA infusion in 
the evidence corpus.
4.2.1.5  Early Synthesis – Concept Mapping
The initial mind map was then used to create a concept map.   A concept map is a 
formalized version of a mind map that can be used by system designers and ontology 
developers.  A concept map highlights unique concepts and the structure is often guided by a
“focus question” or some sort of theoretical framework.213  The focus question was, “How 
would a palliative medicine clinician search for these data and information elements?”  It 
was common to have multiple instances of the same element, such as “respiratory 
depression,” in the mind map as many concepts were mentioned numerous times in the 
evidence.  All instances of identical concepts on the mind map were aggregated into a single
node in the concept map.  Similar concepts on the mind map were likewise collapsed into 
single nodes if it was determined that they represented synonyms of the same underlying 
clinical concept.  Being careful to retain the categorization into groups identified in the prior
mapping exercise, adjustments were made to the structure to locate similar concepts into 
closer proximity within the map.  The result was a graphic map representing each unique 
data or information element used in managing an opioid PCA.
4.2.1.6  Final Synthesis – Information Model
Nodes from the concept map were examined and transferred to a spreadsheet, 
creating a list of unique data and information elements.  This list, along with the concept 
map, was then used to build an information model that represented those data and 
information elements that are important when managing an opioid PCA infusion based on 
concepts reported in the literature over a period of over 50 years (1960 to present).  This 
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information model further formalized the concept map, representing the concepts as real-
world objects,214 in this case, as data might be organized within a typical electronic health 
record.
4.2.2  Results
4.2.2.1  Sample Description
Initial searches identified 315 potential journal articles, of which 225 remained after 
review of articles or abstracts and application of the inclusion and exclusion criteria.  
Throughout the 1970's there was slowly increasing interest in PCA with sporadic 
publications, though the concept was called by a variety of different names.  Articles in this 
time frame were found most often by following citations in later articles.  In the late 1980's 
there was a dramatic increase in the number of publications.  Figure 4.3 shows a graph of 
the number of PubMed-indexed articles published per year when searching on the “patient 
controlled analgesia” used as either a general text string, a title/abstract term, or a MeSH 
term.
 As the model being developed was intended to be representative but not necessarily 
exhaustive, a representative set of literature consisting of 2 major texts in the field, 5 
handbooks and guidebooks, 10 articles specifically selected to be high yield, and 1 protocol 
were selected for initial analysis.  Sources were selected based on the potential yield, which 
was subjectively determined by the comprehensiveness, the length of journal article (with 
preference to longer articles assuming they would contain more detail and data), and the 
frequency that the source was cited by other sources.  A second set of sources to determine if
saturation had been reached was selected and is described below.
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4.2.2.2  Mind Map
When complete, the mind map revealed 4 general categories into which all identified
elements could be placed.  The categories were: (1) elements related to the patient, (2) 
elements related to the treatment plan, (3) elements related to the medication being given, 
and (4) elements related to the pump settings / prescription.  Further organization revealed 
varying levels of subdivisions, depending on the category.  These subcategories are shown 
in Docear's outline form in Figure 4.4.  The entire mind map was quite large, at 
approximately 12 feet tall if printed using a standard font.  A small segment of the mind map
to show the structure is shown in Figure 4.5.
4.2.2.3  Concept Map
In creating the concept map, three categories were retained and directly transferred 
from the mind map: elements related to the treatment plan, elements related to the 
medication being given, and elements related to the pump settings / prescription.  From 
elements in the mind map related to the patient, three distinct categories of elements were 
created in the concept map.  This resulted in 6 categories: (1) patient adverse event data, (2) 
patient pain data, (3) patient context data, (4) treatment data, (5) medication data, and (6) 
pump data.  While this minor restructuring in form in which the data was presented 
increased the ease with which researchers could examine concepts and relations between 
concepts, it had no clinical implications.   The full concept map may be reviewed in 
Appendix A.
4.2.2.4  Information Model
The information model represented all elements from the concept map as objects in a
hierarchical arrangement.  There were two main categories, information related to treatment 
and information related to the patient.  Under each category was a cascade of more specific 
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information elements.  For example, AdverseEvent is an example of patient-related 
information which included the more specific topic of adverse GI_Effects, which in turn 
included instances of nausea, vomiting, and constipation.  The information model can be 
seen in Figures 4.6, 4.7, and 4.8 .
4.2.3 Discussion
Many patients with serious, life-threatening illnesses experience significant, 
complex, and difficult symptoms as a consequence of the disease or disease treatment.  The 
clinical specialty of Palliative Medicine emerged to meet this need.  Treatment approaches 
such as parenteral opioid infusion administered by PCA protocols are important 
interventions in the palliative medicine toolbox that can relieve suffering and improve 
quality of life.  Managing an intervention like opioid infusion via PCA pump is a complex, 
high-stakes endeavor, particularly when doses need to be titrated rapidly in response to 
severe pain.  Unfortunately, palliative medicine clinicians have complained that they lack 
adequate data to make optimal titration decisions; that the information is either not present 
in the record or is too difficult to locate.  Automating the aggregation and presentation of 
relevant information holds the potential to address the problem of missing or difficult-to-
locate information.  Preliminary work revealed that the information flow to support this task 
is complex, and there has been little or no literature evaluating the adequacy and quality of 
data available to clinicians at the point of care, with respect to managing PCAs.  Therefore, 
the first step in designing an informatics solution to this clinical problem was to identify the 
data and information needed for clinical decision making in the identified use case of using 
opioid infusion via PCA pump in the palliative care context.  For aim 1, phase 1, an 
evidence-based information model was developed, based on a systematic review of the 
literature.
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This first phase of aim 1 began with broad literature evaluation and data extraction, 
which was followed by sequential creation of progressively more formalized models.  The 
mind map represents a comprehensive set of elements gleaned from a representative set of 
published literature and PCA protocols, organized into a loosely hierarchical structure.  The 
concept map consolidated and condensed this raw data into a more manageable form, 
retaining but refining the hierarchical structure.  The final step was creation of an 
information model for the clinical use case of opioid PCA infusion management.  This 
information model depicted data and information elements involved in this clinical domain, 
representing them as objects organized into hierarchical groupings of increasing specificity.
A data or information model forms the foundation of any robust CDS application and
increasingly it is recognized that this foundation should be laid using rigorous, standardized 
approaches; traditionally there are three sources from which to build such a model: expert 
opinion, predictive models (based on clinical data), and published literature.2  In cases like 
this where formal, universally accepted guidelines to direct care are lacking, evidence-based
medicine (EBM) approaches, such as systematically reviewing published evidence as done 
here, provides one mechanism to form guiding principles from valid, relevant 
information.215,216  In this domain, a body of evidence existed in the form of well-respected 
articles, texts, and guidebooks.  Though perhaps not true in every case, for most clinical 
domains there likely is such evidence available even if there are not clear guidelines already 
synthesized.  This project was strengthened by the inclusion of real-world protocols but such
protocols, might or might not be available for other domains, depending on the specific 
domain and focus question at hand.
The overall approach used in this project was in no way tied to the domain and could
easily be used in any other similar domain where there is adequate evidence to form a 
corpus for element identification and extraction.  This work used mind mapping, an 
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accepted qualitative approach,198,217,218  to apply principles of evidence-based medicine to 
build the requisite foundation for the proposed CDS application.  Building the information 
model from the ground up using articles and texts ensured that the foundation for this CDS 
would be evidence based.  Incorporating real-world protocols ensured that the information 
model would be relevant to practicing clinicians.  The systematic approach, including broad 
literature searching and extraction of elements until a formally defined point of saturation 
was reached, supplied a degree of rigor to this process.
The tools (see Figure 4.2) and techniques used in this project are domain agnostic, as
well, and thus should be generalizable to other complex clinical domains.  While 
considerable work was required to locate, evaluate, and implement suitable tools to develop 
the pipeline used in this project, once developed, the actual use of that pipeline was 
straightforward.  The task of amassing clinical evidence is common and likely necessary for 
any work to build the foundation of a CDS.  The process of annotating source documents is 
a common task in qualitative analysis.  Based on the author's limited experience and his 
discussion with other researchers experienced in qualitative work, the tools and techniques 
used here seemed no more difficult, and perhaps less difficult to use than other qualitative 
analysis tools and techniques; the time required also seemed consistent with typical 
qualitative work.  The simplicity of Docear's mind mapping features, however, was 
anecdotally noted by both this author and an experienced qualitative researcher to be, while 
adequate for this type of work, considerably simpler than traditional qualitative software.  
Easier use combined with the negligible hardware and software costs compared to other 
software make the approach and the tools developed for use in this project an attractive 
option for those seeking to build similar foundational infrastructures for CDS applications in
other clinical domains.
A limitation of this portion of the work was that the review and annotation was 
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primarily carried out by a single person.  This limitation was mitigated by two factors.  First,
the work was conducted by a domain expert board certified in as a sub-specialist in 
palliative medicine with extensive experience managing PCAs across a wide spectrum of 
care locations from outpatient settings to tertiary medical center ICUs.  This individual also 
has informatics training.  It was felt considerable expertise and intimate familiarity with the 
domain were important to ensure correct interpretation and preservation of semantic 
meaning when identifying, manipulating, and analyzing the data and information elements.  
Second, the work was reviewed in detail, at least weekly, by a second individual who also 
had a background in clinical care (nursing), some experience with palliative care and PCA 
management, and extensive informatics experience.
4.3  Phase 2: Validating the Evidenced-Based Model
4.3.1 Methods
The models synthesized from published evidence and clinical protocols represent 
data and information believed to be important in management of opioid PCAs in palliative 
settings.  However, published literature, protocols, and guidelines may differ from actual 
clinical  practice.219–225  The information model was reviewed by the investigator, a domain 
expert in palliative management of opioid PCA infusions, and by other clinicians, and the 
model appeared to show all data needed to manage an opioid PCA infusion in palliative 
settings.  This informal review suggested the model had at least face validity.  More rigorous
evaluation of other forms of validity was undertaken.
4.3.1.1  Design
Model validation was approached similar to a content validity assessment. Content 
validity, the extent to which all facets of a theoretical construct are represented within a set 
of items in a measure,226 would confirm that the elements obtained from the prior phase 
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encompassed the real-world data and information needs of providers managing opioid PCAs
in palliative settings.  Content validity differs from and complements face validity in that the
evaluation process is more formalized, and is conducted using recognized subject matter 
experts.226
4.3.1.2  Data Collection Methods
Content validity of the model was  assessed through expert review using an approach
based on a Modified Delphi technique.227  The Delphi method is a widely used and well 
accepted method of evaluating consensus from a group of experts; the modified approach 
differs from “traditional” Delphi methods in that the process begins with a list of elements 
rather than asking the experts to construct the list of elements themselves.227,228  The Delphi 
method typically involves multiple rounds of questionnaires that seek to discover then 
progressively refine items until consensus is reached.  Because the purpose for this study 
was simply to assess the perceived completeness of the existing information model, and 
because this model was evidence-derived, a single round was anticipated to be sufficient.227
4.3.1.3  Sampling
Participants in a Delphi study are expected to be domain experts.  Although there is 
not consensus around the metrics for what constitutes an expert, the participants are 
expected to be trained and competent in the clinical domain of interest.227 There is also no 
standard way to determine the number of participants required for a Delphi study, although 
many experts recommend that researchers use the minimum number of subjects necessary to
sufficiently encompass the requisite area of expertise.227 Like usability evaluations, Delphi 
studies with less than 10 participants are not unusual, particularly when the domain is well 
constrained.227
Target participants for this study were health care providers who managed and/or 
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prescribed opioid PCA regimens in palliative settings.  Given the narrow clinical focus of 
the domain of interest and the relatively small national pool of experts available, target size 
was 3-7 experts.  Using a convenience sampling approach to recruitment, providers known 
to the author to be experts in the field were contacted and asked if they were willing to 
participate.  Given the length of the survey (103 data elements) and that the potential 
participants were busy expert clinicians, we anticipated that less than half of those invited 
would respond, so 14 experts were invited to participate.  The survey remained open for 6 
weeks.
4.3.1.4  Survey Design
After Institutional Review Board approval, the expert review and validation was 
conducted using an on-line survey administered using the REDCap survey system, which is 
hosted at the University of Utah.  REDCap (Research Electronic Data Capture) is a secure, 
web-based application designed to support data capture for research studies, providing 1) an 
intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and 
export procedures; 3) automated export procedures for seamless data downloads to common
statistical packages; and 4) procedures for importing data from external sources.229
The survey was constructed similarly to other Delphi studies.  A single vignette was 
presented to the survey respondents to help focus responses on the use case of interest.  The 
vignette described a patient in an inpatient setting who was experiencing pain from a life-
limiting, but not immediately terminal, disease.  For each element from the information 
model, a question was created, asking the expert to rank that element's importance for 
clinical decision making regarding opioid PCA regimen management on a 5-point Likert-
type scale (not important, of minor importance, important, very important, extremely 
important).  In this way 44 basic elements were presented to all participants.  Using decision
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logic based on responses to these basic items, up to fifty-nine additional elements could be 
presented.  For example, when a survey participant indicated that “vital signs” was at least 
important (≥3), he or she was presented with the list of individual vital signs (pulse, blood 
pressure, etc.) from the information model.  If the participant marked “vital signs” as less 
than important(1 or 2), he or she was not presented any of the child elements for evaluation. 
This lead to a possible total of 103 questions that could be presented to participants if all 
decision logic was triggered.  At the end of the section, participants were presented an open 
text box to list any data or information elements that they felt were important but that did 
not appear on the list, or give other comments about elements.  A representation of the 
section of the survey used for this work, formatted for print, is presented in Appendix B.
4.3.1.5  Analysis Plan
The purpose of the survey was to assess the extent to which domain experts 
considered the list of data and information elements to be important for clinical decision 
making for the described use case.   Although the Likert-type question design asked 
participants to consider the level of importance, the primary question was simply, which 
elements ranked at least “important” (response of 3) versus those rankings less than 
“important” (response of 2 or 1).
The primary analytic method was simple descriptive statistics. For each of the data 
and information elements, the average (mean) ranking across the respondents was used to 
determine which elements were important (mean of 3 or higher). Similarly, standard 
deviation (SD) provided an initial estimate of response consistency, using the heuristic that 
SD of 1 or below represented high levels of consensus, and greater SD represented lower 
levels of consensus. Although the use of mean and standard deviation may be viewed as 
“incorrect” from a strict technical standpoint by some because the scale produces ordinal 
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data, these are the most common metrics reported in the literature for Likert-type items,230 
and it has been repeatedly demonstrated that traditional statistical metrics are robust and 
appropriate for these analyses.231
In addition, we used percent agreement and intra-class correlation (ICC) to evaluate 
consensus across some of the sets of items. ICC is an alternative to the more common metric
for determining agreement between raters, kappa. The kappa metric assumes the data are 
categorical, whereas weighted kappa and ICC can be used for ordinal (or higher) data; the 
ICC  is a special case of weighted kappa. An advantage is that, whereas kappa is used to 
evaluate correspondence between two raters, ICC evaluates correspondence across multiple 
raters. A potential limitation is that ICC is computed as a ratio of between-rater and within-
rater variability, and so can only be computed for sets of items (not for individual questions).
Similarly to kappa and correlation coefficients, ICC values can range from -1 to +1.232
Like kappa, there are no hard and fast thresholds for interpretation. It is common for 
opinion-based items to have lower correspondence (agreement in the range of .4 to .6), 
whereas significant agreement on objective measures typically is viewed as values above 
0.7.232   Cohen, the developer of the kappa and related statistics, suggested that values as low
as .41 may be acceptable for health research, particularly with subjective items. He 
suggested the Kappa result be interpreted as follows: values ≤ 0 as indicating no agreement 
and 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as 
substantial, and 0.81–1.00 as almost perfect agreement.233 Given the subjective nature of this
evaluation, and that agreement on the exact level of importance was not the primary purpose
of this analysis, we used these liberal thresholds for interpretation. While it is possible that, 
depending on how the software calculates ICC, the values may be negative, it is difficult to 
interpret the meaning of negative ICC values. Some interpret negative values like a 
correlation, with negative simply showing the direction of the relationship between ratings 
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by different experts; others interpret negative ICC to mean that the variation across items for
a single rater is greater than the variation between raters (that is, that the items in the set may
not be tightly linked); and still others interpret a negative ICC to mean that the true 
correspondence between raters is low.234 When a negative ICC was obtained we examined 
the raw data to aid interpretation.
4.3.2 Results
The validation (expert review) survey was completed by 5 participants (36% of those
invited).  Data were analyzed using Microsoft Excel and Statistical Package for Social 
Sciences (SPSS, version 22) software.  Demographic characteristics suggested that the 
participants were clinical experts in the relevant domain, as shown in Table 4.3.  Four of the 
participants were physicians and one was a nurse practitioner; all were experienced 
clinicians with palliative care experience.  Three of the participants ranked their ability to 
manage opioid PCA regimens as “Competent” and two ranked their ability as “Expert” 
level.
The average ranking and standard deviation for each element of the 103 elements is 
shown in Table 4.4.  There was substantial agreement among the experts, overall, with an 
Intra-class Correlation (ICC) of 0.78 (95%; Confidence interval [CI] 0.71 – 0.84).  No 
additional data or information elements were suggested.  The majority of elements (96; 
93%)  received average ratings corresponding to important (ranking of 3), very important 
(ranking of 4), or extremely important (ranking of 5) for clinical decision making.  For these
elements, there was moderate agreement between expert rankings for these 96 elements with
an ICC of 0.60 (95% CI 0.46-0.71).  Eight elements (7.8%) had unanimous agreement 
across all 5 experts as being extremely important.  Those extremely important elements are 
shown in Table 4.5.
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While most of the items listed on the survey received average ratings of at least 3 
(“important”) across all 5 experts, there were 7 elements (7% of the total) where the average
ranking for the element was “less important” (2), or “unimportant” (1) in terms of 
influencing clinical decision making about PCA dose adjustments.  Those elements are 
shown in Table 4.6.  The ICC for this set of 7 lower ranked items was  -0.16 (95% CI -0.22 
to 0.94); the negative ICC is difficult to interpret.  While some may interpret this as low 
agreement, the raw data and standard deviation suggest acceptable agreement between 
experts for these low-ranked elements, and only genetic profile had a standard deviation of 
higher than 1.
Disagreement between experts for a a number of items was noted.  There were 13 
items (12.6%) where the standard deviation was greater than 1; the ICC for these items was 
0.12 (95% CI -0.96 to 0.69) which indicates was little if any agreement.  For example, one 
of these items, “patient goals of care,” was rated highly by most experts (average rating 4.2 
out of possible 5), but one expert rated this item as “not important,” the lowest level of 
importance, for decision making.  Functional status was similarly ranked as not important by
one expert, but at least “important” by the others. One expert rated the patient’s genetic 
profile as extremely important, whereas the others rated genetic profile as not important or 
of minor importance.
Experts agreed on the importance of items such as interventional and adjuvant 
therapies, but were in less agreement on the importance of non-analgesic pain interventions 
aimed at the underlying cause of pain.  There appeared to be no consensus about patient 
I/O's (fluid “ins and outs”), as this element was ranked differently by every participant.  The 
items for which there was lower consensus among experts (SD>1) are shown in Table 4.7.
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4.3.3 Discussion
The expert review of the information model supports content validity.  There was 
substantial overall agreement (ICC = .78) for the absolute ratings of importance. There was 
unanimous agreement from these experts about the most important items and no new data or
information elements were suggested by the experts.  There was some variation in ratings of 
the level of importance, and a few items with lower agreement about the absolute 
importance rankings (SD between experts greater than 1 for the item). A small number of 
items were identified as less important (mean rating < 3) but no item was ranked as 
completely unimportant (mean rating < 2). Some variability in the absolute rankings about 
level of importance was not surprising, given the subjective nature of the question and lack 
of evidence in the literature about what data elements are important for this use case. 
Overall, the findings support the idea that the items in the information model are viewed by 
expert palliative medicine providers as important for clinical decision making in the use 
case.
4.4 Summary Discussion of Aim 1
Together phase 1 and 2 suggest that the novel approach developed to identify, 
extract, and analyze data elements from literature and protocols was successful.  The 
method, which allowed annotation of standard PDF files (a common file format in which 
many full-text journal articles are readily available) to be carried out on a low cost and 
highly portable tablet device, was a great benefit to this qualitative approach.  The entire 
process handled the volume of PDF files with no difficulty.  Docear, the application used to 
extract, sort, and categorize the annotations, easily handled a sizable mind map with over 
1,500 nodes.  There were no problems with file or application instability when managing a 
mind map of this size, even on a PC several years old and with modest hardware 
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specifications.  Physical size of the mind map would have presented a considerable 
challenge if a 'hard copy' of the mind map was needed; it would be approximately 12 feet 
tall if printed using a standard font size.  However, the zooming and panning features in 
Docear combined with robust search capabilities and the ability to independently collapse 
and expand any branch of the mind map, allowed for relatively easy navigation, 
manipulation, and editing of the mind map, even one of this large size.
The pipeline developed for this project may have application to a wider group of 
qualitative research studies.  The relative simplicity and portability of the process combined 
with the extremely low cost of required hardware and software make this an especially 
attractive method for projects with limited budgets.  Graphical mapping techniques, 
including mind mapping and concept mapping, are accepted methods of analysis and data 
organization in a number of fields.198,217,235–237  This project proved that basic categorizing and
organizing of elements in a branching hierarchy can easily be accomplished by mind 
mapping, even when dealing with a large number of individual concepts.  This suggests that 
mind mapping as a method of initial knowledge engineering in health informatics is a 
reasonable candidate methodology to consider when the need arises to extract elements from
published primary sources to build an information model.
The 4 general categories in the initial mind map emerged quickly and data and 
information elements were easily categorized into one of them.  As extraction progressed, 
elements in each of these 4 categories lent themselves easily to further categorization into 
sub-categories, yielding a hierarchy with little ambiguity or overlap between categories.  
Data and information elements fit rather easily into these categories and sub-categories and 
there was very little strain or difficulty in the process of adding new elements to the existing 
mind map as it developed.  Many elements appeared multiple times, both within single 
sources and across multiple sources, leading to the subjective feeling that data from all 
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sources were relatively consistent and that they reinforced common concepts. The free-form 
mind map was easily and progressively formalized, first to a concept map and then an 
information model, by means of aggregating nodes that had semantic similarity.
The expert review (survey) provided evidence of content validity for the model.  
That no additional element were suggested by the experts indicated that the extent of 
coverage was fairly complete; that is, the model was a reasonably comprehensive list of the 
applicable data and information elements needed for clinical decision making for the use 
case.  The purpose of Aim 1 was to develop a representative, rather than comprehensive, list 
of elements to build a foundation for a display-oriented CDS application. Overall, the results
of this portion of the work indicated that the inductive process was a successful strategy and 




    



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    




















































































































































































































































































































































































































































































































































Figure 4.4 ­ Mind map sub­categories
(Printed in Docear's outline format.)









Assess the e ect of pain on the patient
Response to current therapy
Cause of pain
Pain history
Symptoms or SE d/t opioid














Observations about use of PCA
Dosing variables


















Other therapy targeting the causeof the pain
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Figure 4.5 ­ Mind map
This is a screen capture of a small section of a Docear
mind map showing the structure of a mind map.

















































































22 12 12 50
33 33 25 100
6 6 6 36
10 10 6 3
8 8 8 5
mean 15.8 14.25 11.25 38.8
Stadard Deviation 11.5 12.6 9.2 39.7
Years in 
Palliative Medicine
Years of experience 
managing PCA regimens
Estimated number of PCA regimens 
managed per year
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  Element: MEAN STDEV
Patient's ability to understand and use the PCA 5 0
Patient's ability to comprehend the PCA device and paradigm 5 0
Size of the PCA demand dose ordered 5 0
Ordered frequency of PCA demand doses 5 0
History, timing, and pattern of use of demand doses 5 0
Basal infusion rate 5 0
5 0
24 hour (or other interval) total opioid given 5 0
Whether patient is opioid naive or tolerant 4.8 0.45
Patient's response to opioids before this episode 4.8 0.45
The effectiveness of the current pain regimen 4.8 0.45
The tolerability of the current pain regimen 4.8 0.45
Patient's cognitive functioning 4.8 0.45
4.8 0.45
Cause of pain 4.8 0.45
Effect of the pain on the patient and his/her life 4.8 0.45
Myoclonus 4.8 0.45
Delirium 4.8 0.45
Impaired cognitive function 4.8 0.45
Name of drug in use 4.8 0.45
Route of opioid administration 4.8 0.45
4.8 0.45
Clinician bolus that are/were ordered or available 4.8 0.45
Administered clinician boluses 4.8 0.45
Concurrent orders for oral opioids 4.8 0.45
Use of ordered oral opioids 4.8 0.45
Number and timing of demand doses given 4.8 0.45
Currently used interventional therapies 4.6 0.55
Renal function 4.6 0.55
Patient's description of the pain 4.6 0.55
Nausea 4.6 0.55
Vomiting 4.6 0.55
Impaired motor function 4.6 0.89
Respiratory depression 4.6 0.89
Time when particular PCA parameters started/stopped 4.6 0.55
Loading doses given 4.6 0.89
Number and timing of demand dose requests 4.6 0.55
Interactions with other medications 4.6 0.55
The particular opioid's kinetics 4.6 0.55
Equianalgesic ratios 4.6 0.89
Information about opioids given by other than PCA (ie loading or 
clinician doses, or concomitant orders)
Patient's physical condition (ie organ dysfunction, functional status, 
etc.)
Calculated and trend data about PCA use (totals, demand patterns, 
etc.)
Table 4.4
Average ranking for elements in the survey
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Table 4.4 ­ Continued
Element: MEAN STDEV
Currently used co-analgesics 4.4 0.55
Currently used adjuvant therapies 4.4 0.55
Pain scores/ratings over course of treatment 4.4 0.55
4.4 0.55
Patient's self-rating of pain when moving 4.4 0.89
GI symptoms/side effects 4.4 0.89
Constipation 4.4 0.89
Ratio of demands made to demand doses given 4.4 0.89
Time to peak effect 4.4 0.55
Metabolites and features of metabolites 4.4 0.89
Patient's goals of care 4.2 1.79
Age 4.2 0.84
Non-analgesic treatment directed at the cause of the pain 4.2 1.3
Currently prescribed bowel regimen (laxatives, stimulants, etc.) 4.2 0.84
Patient's vital signs 4.2 0.45
Hepatic function 4.2 0.84
Episodes of breakthrough pain 4.2 0.84
Location of the pain 4.2 0.84
Quality of the pain 4.2 0.84
Aggravating factors 4.2 0.84
Alleviating factors 4.2 0.84
Patient's self-rating of usual pain 4.2 0.84
Patient's self-rating of pain at its worst 4.2 0.84
Patient's self-rating of pain at its least 4.2 0.84
Patient's self-rating of pain at rest 4.2 0.84
Pulmonary symptoms/side effects 4.2 0.84
Hallucinations 4.2 0.84
Sedation 4.2 1.1
Dose forms available (other routes, dosages, etc.) 4.2 0.84
Patient's psychological condition 4 0.71
Respiratory rate 4 1
Duration of the pain 4 0.71
Neurologic symptoms/side effects 4 1
Urinary retention 4 0.71
Dysphoria 4 1
What "limits" (1hr, 4hr, etc.) are set 4 1.41
If or when limits were reached (and pump locks out) 4 1
Patient characteristics such as age, weight, sex 3.8 0.45
Weight 3.8 0.84
Pulseoximetry 3.8 0.84
Baseline cognitive status 3.8 0.84
Respiratory function 3.8 0.84
Patient's rating of pain under different circumstances (ie best, 
worst, typical...)
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Table 4.4 ­ Continued
Element: MEAN STDEV
Radiation of the pain 3.8 1.1
Half-life 3.8 1.1
Receptor profile (agonist, agonist-antagonist, etc.) 3.8 0.84
Hypotension 3.6 0.89
Pulmonary edema 3.6 0.89
Blood pressure 3.4 0.89
Functional status 3.4 1.52
Skin symptoms/side effects 3.4 1.14
Underlying cardiopulmonary disease 3.2 1.3
Hydration status 3.2 1.3
Rash 3.2 0.84
Hydrophilic/hydrophobic and Lipophilic/Lipophobic characteristics 3.2 1.1
I/O's (fluid "ins and outs") 3 1.58
Injection site irritation 3 1
Itching 2.6 0.55






Patient's genetic profile potentially affecting opioid metabolism, 




Elements rated "extremely important” by all experts
Patient Context Elements:
Pump Related Elements:
   Size of the PCA demand dose delivered
   Ordered frequency of PCA demand doses
   History, timing, and pattern of use of demand doses
   Basal infusion rate
   Information about opioids given by other than PCA
   24 hour (or other interval...) total opioid given
   Patient's ability to comprehend the PCA device and paradigm
   Patient's ability to understand and use the PCA
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Table 4.6
Elements ranked as less important
Element Mean SD





Cost of medication 2.60 0.55
Patient Characteristics:
Patient's sex 2.20 0.45
2.20 1.64
Patient's genetic profile, potentially affecting 
opiod metabolism, effect, or side effects
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Table 4.7
Elements with low agreement
Element Mean SD
Symptom/ Adverse Event Related Elements:
Skin symptoms 3.40 1.14
Sedation 4.20 1.10
Pain Related Elements:
Radiation of the pain 3.80 1.10
Patient Context Related Elements:
2.20 1.64
Patient goals of care 4.20 1.79
I/O's (Fluids “ins and outs”) 3.00 1.58
Functional status 3.40 1.52
Hydration status 3.20 1.30
Underlying cardiopulmonary disease 3.20 1.30
Treatment Related Elements:
4.20 1.30
Medication information related elements:
Drug half-life 3.80 1.10
3.20 1.10
Pump Related Elements:
What limits (1hr, 4hr, etc.) were set 4.00 1.41
Patient's genetic profile, potentially affecting 
opiod metabolism, effect, or side effects
Non-analgesic treatment directed at the cause 
of the pain
Drug hydrophilic/hydrophobic and 
lipophilic/lipophobic characteristics
CHAPTER 5
FHIR TO REPRESENT PCA DATA
5.1 Background
The overall goal of aim 2 was to assess the adequacy of the emerging HL7 standard 
FHIR to represent the data elements used by the proposed CDS application.  Theoretically, 
the CDS application could be system-agnostic if it could be developed with a system-
independent way to request and receive the needed data.  The FHIR standard is an emerging 
standard intended to allow such cross-platform use of data.
 In the past, applications such as this proposed CDSS would have been developed 
within the EHR itself, tightly coupling the application to a single EHR system.  Now, many 
in health IT are exploring methods to loosely couple CDS applications to EHR systems.  In 
such new paradigms, interfaces and CDS applications are modular and can be deployed on 
multiple systems and platforms.  This could allow users to have a customized experience 
meeting their specific needs regardless of the underlying platform.  Such modularity 
requires standardization of the connections between the underlying system and the user-
facing modules, such as applications and interfaces.  FHIR is one mechanism proposed by 
which these modules could connect to, or interface with, an existing EHR.
In the past, other standards to meet this need have suffered from being difficult to 
use due to being highly complex, or from being overly simplistic and therefore not able to 
accurately represent the data at a granular and specific enough level to adequately fulfill the 
clinical need.  FHIR has been developed to address both of these concerns.  The FHIR 
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paradigm is based on packaging data within resources which are general and flexible, 
allowing a small number of resources to represent a wide variety of health data types.  This 
constrained initial set of resources theoretically allows ease of use and implementation.  
While the set of existing resources are expected to meet the needs of 80% of clinical use 
cases, FHIR has a formal extension process to fill the gap where existing FHIR resources 
don't adequately represent needed data.1  There are likely many clinical scenarios where 
representation of some of the necessary data will require extension, and applications 
supporting these use-cases need to have full interoperability with existing systems.
As the ease of both use and extension of FHIR will impact its adoption, it is 
important to assess both early on in its development.  If use or extension is difficult, FHIR 
may offer little benefit over current standards.   To showcase and test this new standard, a 
number of prototype applications have been developed that make use of common data and, 
anecdotally, FHIR appears easy to use.  However, FHIR is still untested in many domains 
with a paucity of published literature describing its formal use and application.
In order to assess FHIR's robustness, a gap analysis was performed to probe how 
well the standard could be used as a mechanism to transfer information represented in the 
model developed in aim 1 from a data store, such as the EHR, to the theoretical opioid PCA 
CDSS proposed.  The goal was to determine, with respect to this use case, what gaps existed
in the existing FHIR resources (i.e., data or information that could not be adequately 
represented by existing FHIR resources and thus required extension), and to assess the ease 
with which those gaps could be filled by extension.
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5.2 Methods
5.2.1 Enrichment of the List of Data Elements
In order to perform the gap analysis of FHIR, a formal list of the elements used for 
decision making when managing an opioid PCA was required.  The information model 
created from the literature in Aim 1 was the starting point.  This evidence-based model 
included a wide variety of concepts, from discrete numeric data to complex concepts 
representing general states of health.  To further quantify elements prior to mapping and to 
increase the granularity of shared understanding about them, descriptive metadata about 
each piece of information were added.  This shared understanding was expected to increase 
the accuracy of subsequent mapping.  The enrichment activity was performed by two 
reviewers in collaboration.  Both reviewers had extensive clinical experience in the use of 
opioid regimens and the PCA paradigm, as well as formal informatics training and 
experience.  First, several categories of metadata and the coding scheme were developed.  
Each element was then transferred from the information model to a spreadsheet where 
metadata was added.
The first attribute added was the level of information as described in the DIKW 
theoretical framework.  This hierarchy has roots as far back as the 1930 but gained popular 
attention in the late 1980s and early 1990s.238,239  This framework stratifies information 
across a pyramid structure with meaning increasing from the lowest layer to the highest 
layer.  See Figure 5.1.  Data, the lowest level, consists of symbols which can be described 
objectively without interpretation.  The next higher level, labeled Information, is composed 
of data that are interpreted or structured.  Knowledge, the third layer, is information that has 
been synthesized and formalized.  The highest layer is Wisdom, which is knowledge applied
in context to answer the question, “why.”240,241  Each element was marked with a “D”, ”I”, 
“K”, or “W” corresponding to the level of meaning that best described the element.  For 
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instance, the element “pain score” referred to simple, discrete, numeric data without 
contextual information or interpreted meaning.  While a score may be attributed meaning by 
the provider, representing a numeric pain score requires only the numeral itself (the scale on
which the rating is needed for interpretation, but with respect to the score itself, only the 
numeral is required).  The element “pain score” was therefore assigned a DIKW level of 
“D” for data.  In contrast, the element “hypoxia” was an interpretation about the oxygen 
saturation and required comparison of a given score against a known standard to determine 
whether the condition or state of hypoxia was present.  Hypoxia was therefore ranked as “I.”
Elements requiring more complex processing and conveying a higher level of meaning, such
as the element “presence of breakthrough pain: end dose failure” were labeled “K” for 
knowledge.  A very few elements were quite complex, requiring a deep understanding of the
context and meaning, so were categorized “W” for Wisdom.
Next, each element was categorized according to a 'data type.'  The data types were 
state, occasion, or recurring.  State was defined as an ongoing condition of a patient such 
that the moment of observation is only one point of many instances when the patient would 
likely be in that condition.  The state is expected to exist over a much longer time period 
than the moment of the single observation.  Examples of states included dehydration, 
constipation, reported typical pain at rest, cause of the pain, age, sex, renal function and 
opioid naïve/tolerant.  States vary in their degree of permanence.  The state of a patient's sex
would be rather permanent, while 'dehydration' might be a state which could change over 
hours.  In contrast, an element which describes the patient's condition or actions at a given 
single point in time, with no intended inference that the condition exists at any other time 
than that moment, was considered an occasion data type.  Occasion data can be applicable to
a patient over a considerable period of time, though the condition is not necessarily 
considered to exist before that or after the observation.  The focus is that at the moment of 
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documentation of the occasion element, the patient had or did not have the characteristics of 
the data element in question.  Occasion data define what a patient is doing, or something 
that is happening at the instant it is happening.  Examples of elements of the occasion type 
include most symptoms, such as an episode of nausea or vomiting, an episode of 
hallucinations, and the presence of sweating.  Elements of the recurring type were defined as
those measurable concepts for which some value exists at any and all points in time, with 
the observed value indicating the value at the instant of observation.  Measurement and 
documentation of recurring type data occurs frequently at set intervals often with the intent 
to compare values across time.  An example is a patient's blood pressure – a living patient 
always has a blood pressure, but it is only measured periodically.  Other examples of 
recurring type elements include weight, other vital signs (temperature, pulse, respiratory 
rate), and pain scores.  Two other data types, constant and calculated, were added for 
elements that did not fit well into one of the above categories, but these were rarely used.  A 
constant data type was defined as some characteristic that could not change; an example 
would be the name of a medication itself (i.e. while morphine can be given by different 
routes, in different doses, and at different times, it is never anything but morphine).  The 
calculated data type was used for data or information that was mathematically derived from 
some other data, such as “total morphine given in 24 hours.”  This could be a state the 
patient was in – having received a certain amount of medicine in a set time, but for clarity, it
was chosen to add this data type; it was only used for data elements related to pump data.
Third, for each element in the model, a proposed method of communicating or 
displaying that element to the user was determined. For simple data, this was usually direct 
display, such as displaying individual pain scores.  More complex topics, however, could be 
directly displayed at that complex level, or the CDSS could present more atomic data, 
allowing the user to infer the presence of the condition from those data.  The handling of 
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such complex topics has a direct bearing on what information is passed to the CDS, so 
agreement on this handling is a critical step prior to mapping.  For example, one element on 
the information model was end dose failure, a condition that occurs when a patient 
experiences repeated escalation in pain scores just prior to the next scheduled dose of an 
analgesic.  A decision support system could either report that the condition of end dose 
failure has occurred, or the system could display pain scores along with dosing information 
and allow clinician-users to make the inference for themselves.  In the latter case, the CDS 
itself never directly deals with the concept of end dose failure, so there is no need to map 
“end dose failure” to the standard.  In the first case, however, where the system indicates to 
the user that end dose failure has occurred, two options are possible.  The CDSS can either 
make the inference that the condition is present from required data, or it can merely relay 
that the condition has been documented in the clinical record to have been present.  In the 
first case, while the data required to make the inference must be transmitted to the CDSS, 
the concept of “end dose failure” itself need not be mapped to the standard for transmission. 
In the second case, it is necessary to map the concept of “end dose failure” to the standard.
Once the decision had been made as to whether the CDSS would require the concept 
itself to be transmitted from the data source or whether the raw data would be transmitted 
and the inference made by the user or logic within the CDSS, elements were marked 
accordingly.  Those elements felt to be best handled by transmission of the complex concept 
itself from the data store were marked with a “D” for directly displayed; elements for which 
inference, either by the clinician or the CDSSS, was thought to be appropriate were marked 
“I” for inference. 
Finally, based on metadata generated for each element so far, a proposed target 
location of specific data or information in the clinical data source for the element was then 
determined and listed for each element.  For elements typed as 'data' in the DIKW 
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framework with a proposed direct method of display, the target location was usually a single
field in the clinical data store where the piece of data was expected to be found.   For more 
complex concepts, especially those for which multiple pieces of data could be used to infer 
the concept, the entry listed was the location(s) of the basic data on which that complex 
concept could be inferred.
5.2.2 Mapping to FHIR – Gap Analysis
Once metadata had been added to the elements from the information model, this list 
of elements was mapped to resources in the FHIR standard to perform the gap analysis.  
Two reviewers separately and independently mapped each element to a FHIR resource.  For 
those elements that were listed as inferred and relied upon, other more atomic concepts or 
data, the FHIR resource chosen was that which would best transmit that basic data to 
calculate or infer the element in question.  Once individual mappings had been established, 
the two authors compared their mappings and reviewed the results, resolving any 
discrepancies by consensus.  A third reviewer, an expert in standards and their application 
with considerable experience with other HL7 standards, was selected to arbitrate any 
remaining discrepancies which could not be resolved by consensus of the two reviewers.
5.3 Results
Initial inspection of the information model revealed 102 distinct pieces of data or 
information.  Consensus regarding types and categories of metadata and the values for the 
metadata for each element was easily reached between the two reviewers.  Enrichment with 
metadata related to DIKW level, data type, method of display, and location in the health data
store resulted in the final enriched list of elements to be mapped to FHIR seen in Table 5.1.
The reviewers mapped all elements except an element related to genetic data, and the
element “presence of appropriate treatment targeting the cause of the pain.”  When 
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comparing mappings, the reviewers found that they had nearly identical thoughts on these 
two elements: the concepts themselves were too vague to make a determination of which 
FHIR elements to use.  These 2 elements were left in the data set for analysis and considered
elements for which the reviewers agreed on mapping.
Of  the 102 elements, in independent review the reviewers picked the same FHIR 
resource to represent the element in 88 cases.   This yielded an overall percent agreement of 
86% with a Cohen's Kappa of 0.776.  On closer review, 5 of the 14 discrepancies were due 
to a new FHIR resource that was added to the draft standard after the first reviewer 
performed his mappings, but before the second reviewer had mapped the elements.  This 
new FHIR resource, “DeviceObservationReport,” was used by the second reviewer for data 
that could be readily obtained through an interface between the PCA pump and the EHR.  
The reviewer who mapped prior to the addition of this more specialized resource chose 
Observation.  If one looks at the 97 elements which this anomaly did not affect, the percent 
agreement was around 91% and the Cohen's Kappa was 0.83.
Of the 14 elements which were mapped differently on independent review, the two 
reviewers easily reached consensus on all elements and did not need to discuss any 
mappings with the identified third reviewer.  Table 5.2 lists the elements mapped, each 
reviewer's individual mapping choices, and the final agreed-upon FHIR resource.
Once agreement had been reached regarding the FHIR resource used to represent 
each of the elements, a model representing use of FHIR resources by the CDSS was 
developed.  This model is displayed in Figure 5.2 as an architecture-style diagram 
illustrating the interactions of various parts of the health IT system involved in storing, 




Results indicate a very high level of agreement between the two individuals mapping
the elements from the information model to FHIR.  Using levels proposed by Cohen, a 
Cohen's Kappa of 0.773 for all 102 elements suggests “substantial agreement.”  If one 
excludes the 5 elements affected by the addition of a new resource to the FHIR standard 
during the study, between the time when each reviewer performed independent mappings, a 
Cohen's Kappa of 0.83 is regarded by Cohen as “near perfect agreement.”233  This is highly 
significant agreement as by the nature of this data set, the so-called “prevalence paradox” 
probably causes the Cohen's Kappa statistic to estimate agreement conservatively.242,243
In initial mapping, there were two elements the which both reviewers independently 
felt could not be mapped to FHIR.  Prior to discussion, for these elements, both reviewers 
felt this had little to do with FHIR but rather to do with the vague nature of these 2 elements 
themselves.  Both reviewers felt that “genetic data” does not currently have a place in 
clinical practice – the underlying concept is, at best, theoretical with nebulous and uncertain 
meaning, and there is not a consistent or accepted way to represent or communicate such 
data in clinical practice.  While it is a fascinating subject for research and no doubt involved 
in the variability of response to opioids seen in different patients, neither author is aware of 
any test or specific genetic information or testing that presently plays a part in clinical 
management of opioid regimens.  As such, this concept does not represent real, current data 
that could be used.  The reviewers also independently noted that the element “Presence of 
appropriate treatment targeting the cause of the pain” was a problematic concept for a CDSS
to capture or handle.  Not only does the concept of “appropriate treatment” requires intricate
synthesis of dozens or more different pieces of data, which specific pieces of data are 
needed is highly context dependent, varying widely from situation to situation.  Without 
further clarification or more detailed specification, this concept was felt to represent a 
88
concept beyond the scope of a real-world CDSS at the present time.  The reviewers agreed 
that with the exception of these two, all other elements of the information model could be 
easily represented by the FHIR standard.
A number of other conclusions can be reached by observing the results of the FHIR 
mapping activities.  First, the currently available FHIR resources are relatively 
comprehensive.  At least in this case, they completely covered the pertinent elements of the 
domain  in question – management of opioid PCA infusions in palliative settings.  Only two 
elements from the information model could not be mapped, but it was determined that both 
were complex, vague, and in fact more theoretical concepts than discrete information used 
in real-world practice.  In fact, these particular elements had been problematic previously 
and were nearly discarded from the model earlier in the process.  In essence, the reviewers 
agreed that by all practical standards, FHIR provided 100% “real-world” coverage of this 
use case without extension.
A second finding is not unexpected – FHIR is still evolving.  This was demonstrated 
by the addition of a new FHIR resource, DeviceObservationReport, to the FHIR standard 
between the time when one reviewer mapped elements to FHIR, and when the second did.  
The availability of this resource to the second mapper but not the first obviously caused 
discrepancies in mapping activities.  Evolution is to be expected of a standard still in draft 
format.  Once the standard is finalized this should be less of a problem, as additions will be 
less frequent and follow a formal protocol, such as introduction at set intervals.  This does 
highlight, though, that it will be important for institutions using FHIR to have policies and 
procedures in place to deal with similar updates, even once the standard becomes finalized.
Third, FHIR was found to be highly flexible with only 8 distinct FHIR resources 
covering all data and information elements in the model.  FHIR was found to be so flexible, 
in fact, that there was considerable overlap between several resources, such as between the 
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condition and observation resources.  This is a known phenomenon; that a concept or data 
element can be modeled using either resource is openly addressed on the FHIR web site.244  
This sort of flexibility, however, caused discrepancies in the reviewers' independent 
mapping, though during discussion these discrepancies were found to be the result of a 
lower level of either the shared understanding about the data or the concept definition, rather
than any feature of the FHIR standard or FHIR resources themselves.  For instance, one 
reviewer considered constipation a condition of the patient, documented by staff as such, 
and so mapped the concept to the FHIR “condition” resource.  In contrast, the other 
reviewer felt the concept of constipation as used by the CDS should be based on the lack of 
a charted bowel movement over a specified interval, so that reviewer chose the FHIR 
resource “observation” to transmit the data needed to the CDSS which would determine if 
the patient met the criteria for constipation.  In discussion, both reviewers were able to see 
the rationale behind all such discrepancies and agreed there could be more than one correct 
way to map the element to FHIR.  
All discrepancies were easily resolved by consensus once the reviewers discussed 
and agreed on type of data and originating location for the data.  For example, once both 
reviewers decided between whether the CDSS would display constipation based on the 
presence of a charted condition of constipation or based on logic calculating length of time 
between charted instances of bowel movements, consensus on the FHIR resource was easily
achieved.  This highlights a significant challenge for implementers, as in the real world there
are often different ways of thinking about the same clinical concept.  Thus while flexibility 
can be a strength of the FHIR standard, flexibility comes at the cost of less intrinsic 
explicitness within the standard.245,246  To avoid pitfalls, it will be absolutely crucial for 
implementers to be very specific about data and concepts and to have a shared 
understanding at a very granular level of the data being transmitted prior to attempting to 
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use FHIR.
While the lack of intrinsic explicitness creates the potential for sub-optimal shared 
understanding to undermine the interoperability it promises, the flexibility of the FHIR 
standard appears to be a great asset.  Unfortunately, adjustments to the FHIR standard itself 
to increase explicitness could negatively impact this flexibility.  Measures to address this 
lack of explicitness which do not alter the standard or it's elegant design are thus preferred.  
Fortunately there are several steps that could be taken to address the potential problems.
First, developing detailed implementation manuals and support documents would be 
quite helpful.  These documents should standardize how implementers make use of and 
interpret the FHIR standard and its associated resources.  For example, such documents 
could give further details on when to use the observation resource versus the condition 
resource, which is an issue recognized on the FHIR website.  HL7 has a history of 
producing such documents and this may well be part of the long-term plan; FHIR is 
currently in draft standard form and documentation should not be produced until it moves 
past this very malleable form.
Second, FHIR training materials should explain clearly and in simple terms the need 
for specificity in underlying data models themselves.  An advantage of FHIR is its simplicity
but this also makes its use within the grasp of individuals with little experience and less than
ideal training in medical informatics.  These individuals need to understand the larger 
process of using FHIR, including the process of creating adequate and detailed models prior 
to its use, so simple guides limited to FHIR itself fall short; information on using FHIR in 
context is desired.  These resources need to be clearly worded with simple yet thorough 
examples as highly technical language or complex examples could be beyond the reach of 
those individuals who most need to understand the danger.
Lastly, a wide variety of “pre-implementation” demonstration artifacts, such as 
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example models, should be made available.  These artifacts should give concrete examples 
of both good and bad development practice so as to clearly point out both the elegance of 
FHIR and the very real pitfalls.  While not specifically related to FHIR, showing these 
artifacts would convey a more accurate picture of the use of FHIR in context and could 
highlight the absolute necessity of laying a solid ground-work before the application of 
FHIR to a project.
92
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.1 Discussion of Current Work
Despite unprecedented medical advances in the last century, the problem of untreated
and under-treated pain resulting from end-stage disease remains largely unaddressed.  
However, it is estimated that 90% of that pain could be adequately treated using currently 
available modalities.80,247–252  The problem, then, lies not in a lack of adequate treatments or 
the need to make new discoveries, but in the application of available knowledge and 
techniques.  The PCA paradigm holds the promise to improve pain control for those 
experiencing late life pain, however, providers using this modality have identified that 
accessing accurate and complete data is a challenge.  As one well accepted function of 
medical informatics is to make the right information available to the right person at the right
time, the discipline of medical informatics should be uniquely situated to respond to this 
challenge.  A second challenge was identified in preliminary investigations: though a 
domain replete with loudly voiced expert opinion, this domain lacks both clear evidence-
based guidance for decision making and clear articulation of the particular information 
needed to make decisions.  The application of relatively standard techniques within the field 
of medical informatics proved successful at overcoming this second challenge, resulting in 
the creation of several key components of the infrastructure for a possible Clinical Decision 
Support System for the domain that could meet the first challenge.
The challenge of understanding the information needs and data requirements that 
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inform decision making when managing an opioid PCA, particularly in a palliative setting, 
was addressed by applying information extraction and mind mapping techniques to a body 
of evidence comprised of published literature and clinical protocols.  The result was an 
information model which was validated by expert review using a modified Delphi 
technique.  This validation proved the inductive approach as developed was successful.  The
challenge of supplying needed information to clinicians at the point of care was addressed 
by examining the feasibility of using the emerging HL7 FHIR standard, currently in draft 
form, as a means to represent requisite data.  This second portion of the work suggests that 
existing FHIR resources are sufficient to convey concepts, information, and data required 
for clinical decisions making when managing an opioid PCA in a palliative context.
The successful use of informatics techniques to address these challenges is important
to the field in several ways.  First, the successful use of an inductive approach to build the 
necessary evidence base to support a CDS system has wide application across other clinical 
domains.  Developing a firm foundational understanding of the information requirements of 
clinicians in a given domain is a crucial first step to building a successful CDS system.  This
cannot be understated.  To that end, the inductive process developed for this project proved 
capable of handling a large body of evidence efficiently and with relatively minimal 
investment in hardware or software solutions.  All software used were available as 
inexpensive stand-alone applications, as open source projects, or as free versions with 
limited but sufficient functionality for this project.  Hardware requirements were modest, at 
most, and are commonly available to researchers and developers.  The use of the 
applications in the process was fairly straightforward, and someone with moderate computer
abilities could likely become proficient in their use with a minimum of effort.  The use of 
mind mapping in particular proved to be a very useful way of dealing with the data extracted
from the body of evidence, and the application Docear proved a very robust tool for the task.
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In fact, after using the application heavily over a few months, this author is left with the 
feeling he has just scratched the surface of the capabilities of Docear.
The use of FHIR to represent data involved in a domain typically thought of as a 
“niche” case , here the clinical use case of opioid PCA management, evaluated FHIR's 
flexibility.  That all data and information elements necessary for decision making when 
managing an opioid PCA in a palliative setting could be mapped to FHIR without extension 
demonstrates the robust flexibility of FHIR to cover even less common real-world scenarios.
FHIR is being developed specifically to be easy to implement and this project affirmed that 
as well.  Both reviewers in this project felt that the FHIR specification and resources were 
easy to understand and manipulate.  As the standard is so new, a current question is whether 
the FHIR specification is robust enough to handle real-world clinical challenges.  This work 
is one attestation that the FHIR specification is flexible enough to handle yet another clinical
domain, in this case, one which is a bit off the beaten path.
Several disadvantages of FHIR were suggested by this work and, though stated 
earlier, do bear repeating.  The reviewers involved in mapping elements to FHIR resources 
frequently found that even slight discrepancies in understanding of the concept underlying 
the element, or differences in opinion as to what specific data an element referred to in the 
storage model, resulted in differing suggestions for which FHIR resource to use.  Given 
FHIR's extreme flexibility, it is incumbent on the individual or team building or 
implementing an application to develop a granular enough shared understanding between all
involved to avoid these sorts of discrepancies.  It is concerning that this lack of explicitness 
could result in multiple representation schemata for similar concepts, undermining the 
purpose of a standard.  Further, as FHIR is quite easy to use, it will be within the reach of 
many implementers who lack experience and understanding to realize the importance of 
explicitness when working with complex health data.  It remains to be seen whether users 
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will realize the need to provide explicit descriptions of data and then preserve that 
explicitness throughout the system; and if they don't, what problems may result.  The 
potential for a situation where lack of explicitness undermines the utility of a standard, 
eroding the potential interoperability it is intended to facilitate, is certainly real.  While its 
potential mis-application in this way is not a fault of the FHIR specification itself, it is a 
potential danger of which one should be aware in light of the interest and current publicity 
surrounding FHIR and its likely coming widespread use, and one which HL7 should address
with, among other methods, robust but clear training materials and thorough examples of 
proper use.
6.2 Potential Future Work
This work focused on the development of the foundational infrastructure for a CDS 
application that could provide timely and needed information to clinicians when managing 
opioid PCA infusions in palliative settings.  In the short-run, this work on the foundational 
infrastructure paves the way for work on the technical infrastructure and, eventually, the 
development of a functional application.  The FHIR specification includes many 
terminology bindings based on the resource used, and the immediate next step is to evaluate 
how well these map to the data representing and supporting concepts in the information 
model developed in this project.  It is also necessary to evaluate the extent to which accurate
data exists within real-world EHRs and other data stores corresponding to the data and 
information elements needed by this CDSS.  In reality, any CDS application is constrained 
to that data and information which is reliably available in the stores of the health 
information systems upon which it is deployed.  Interfacing PCA pumps to the EHR could 
be of great benefit in this regard, as it would provide an automatic way to move information 
into the EHR that currently relies on humans as a conduit.  Such an interface should provide 
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a reliable and accurate source of information for the CDS application.  Once work to ensure 
needed information is available to the CDS, the structure of XML or JSON messages as the 
payload of FHIR resources needs to be developed and tested.  Once this technical 
infrastructure is in place, it is possible to proceed to development of a functioning prototype 
that converts this data into a visualization screen in a manner which is is palatable to 
providers.  Such an application should then undergo iterative testing and optimization, to 
determine if the ultimate goal of a CDSS, tangible improvements in the care of patients, can 
be realized.
While developed specifically for the use case of opioid PCA management in 
palliative settings, this CDS holds the potential to be useful in other settings.  It was 
mentioned in Chapter 2 that an opioid PCA infusion regimen is a specialized mode of 
providing opioid therapy.  In fact, many of the concepts germane to managing opioid PCAs 
are similar to those used in opioid management in general.  While for this work the scope 
was kept narrow, with minor modification this CDS application could be adapted to support 
opioid management in many other settings.  The closely related clinical scenarios of PCAs 
used in the post-operative setting is a logical next step, but other scenarios where opioids are
administered parenterally could be supported by this application.  Wider application 
includes the management of other methods of delivery, such as implantable pumps 
delivering opioid directly to the CNS, or complex oral regimens.  While the system 
envisioned for the short-term is a passive CDS application functioning as a relevant data 
display, it is certainly possible to extend functionality and create an active CDS system.  As 
this project broadly defined the information needs of expert clinicians when making 
decisions for this use case, all data needed for an active CDS system which would issue 
alerts, offer optional general assistance with management, and provide specific suggestions 
based on the patient's unique clinical situation should be present and available within the 
107
CDS system.  To extend this system and create an active system would require only the 









PCA candidatecapable of using PCARationale:capable of using...





Locus of controlRationale: locus
Fear of Opioid present?Rationale: fear
DATA
Prior opioid exposureOpioid Tolerant
documented H/o Opioid abuse
Rationale: opioid tolerant
Opioid NaiveRationale: Opioid-naive pt
Physicial condition
Functional statusRationale: functional status






HepaticLiver labs (ALT, AST, GGT, Bili, etc)
Rationale: liver disease





Hydration statusRationale: hydration status
Rationale: dehydration














pan (see separate section)









Need to adjust other meds accordingly
High dose +Qt intRationale: QT
EKG: qt intervalRationale: ekg




Dose forms availableRationale: dosages available
Drug-drug interactionsRationale: drug interactions
rationale:need to know kinetics
active/toxic MetabolitesRationale: metabolites
Receptor (agonist, ag/antag, partial ag)Rationale
Lipophilic/hydrophilicRationale: lipophilic
Time to peak efRationale: time to peak
1/2 lifeRationale: 1/2 life
Equianalgesic ratiosRationale: equianalgesic dose
Routes availableRationale:Route of admin
TREATMENT
INFOTx targeting cause of painRationale: ...targetting cause...
Interventional therapiesRationale: Interventional therpies
DATA
Adjuvants currently usedCheck med list for any of these and indicate if present
Rationale: adjuvant meds










demandsFor every timedemand requested
Amt given
Delivered? given or not
Time requested
When demands madeRationale: whenthey were made
# demands requested
# demands given
Rationale: number of demands




Compare to pain scores1
Rationale:demand dose trending
Hourly use of demand dosesRationale: Demand dose trending
Totals of other intervalsRationale: drug comsumption
24hr use totals
Opioid given as infusion (hr*mg/hr where no change in med)
# demands requested: when, if given, and dose of each
PROCESS: Conversion to Oral2
1
Rationale: 24h total opioid
DATA - initiationLoading doseRationale: load suf
Rationale: initial loading dose
DATA - ongoing
Rationale: changes to prescription TimeStop
TimeStart
Clinician bolusRationale: dosing varialbes
Can trigger a lockout event = when med stopsLockout event stop time
Lockout event start time
Limit -1hrRationale: Limits
Limit - 4hrRationale: Limits
Basal RateRationale: Basal Rate
Lockout IntervalRationale: Lockout Interval
Demand Dose SizeRationale:demand dose size
RouteRationale: choice of route















1. What Is “FHIR” and why should you care? INTERFACEWARE Inc. 
http://www.interfaceware.com/blog/what-is-fhir-and-why-should-you-care/. Accessed 
April 23, 2015.
2. Greenes RA. Clinical Decision Support: The Road Ahead. Academic Press; 2011.
3. Olshansky SJ, Carnes BA, Cassel C. In search of Methuselah: Estimating the upper 
limits to human longevity. Science. 1990;250(4981):634-640.
4. Walsh D. Palliative Medicine. 1st ed. Saunders/Elsevier; 2009.
5. Lynn J, Teno JM, Phillips RS, et al. Perceptions by family members of the dying 
experience of older and seriously ill patients. Ann Intern Med. 1997;126(2):97-106.
6. The goals of medicine: Setting new priorities. Hastings Cent Rep. 1996;26(6):S1-S27.
7. Moseley KL, Silveira MJ, Goold SD. Futility in evolution. Clin Geriatr Med. 
2005;21(1):211-222. doi:10.1016/j.cger.2004.08.005.
8. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global 
Burden of Disease Study. Lancet. 1997;349(9061):1269-1276. doi:10.1016/S0140-
6736(96)07493-4.
9. Saunders C. Forward: Oxford Textbook of Hospice and Palliative Medicine. In: 
Oxford Textbook of Hospice and Palliative Medicine. 3rd ed. Oxford; New York: 
Oxford University Press; 2004:xvii - xviii.
10. Riley GF, Lubitz JD. Long-term trends in Medicare payments in the last year of life. 
Health Serv Res. 2010;45(2):565-576. doi:10.1111/j.1475-6773.2010.01082.x.
11. Shanawani H. Meeting physicians’ responsibilities in providing end-of-life care. 
CHEST J. 2008;133(3):775. doi:10.1378/chest.07-2177.
12. Billings JA, Keeley A, Bauman J, et al. Merging cultures: palliative care specialists in 
the medical intensive care unit. Crit Care Med. 2006;34(11 Suppl):S388-S393. 
doi:10.1097/01.CCM.0000237346.11218.42.
13. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: 
associations with end-of-life conversations. Arch Intern Med. 2009;169(5):480-488. 
doi:10.1001/archinternmed.2008.587.
127
14. Somogyi-Zalud E, Zhong Z, Hamel MB, Lynn J. The use of life-sustaining treatments 
in hospitalized persons aged 80 and older. J Am Geriatr Soc. 2002;50(5):930-934.
15. Lubitz J, Beebe J, Baker C. Longevity and Medicare expenditures. N Engl J Med. 
1995;332(15):999-1003. doi:10.1056/NEJM199504133321506.
16. McCue JD. The naturalness of dying. JAMA. 1995;273(13):1039-1043.
17. Doyle D. Oxford Textbook of Palliative Medicine. 3rd ed. / edited by Derek Doyle ... 
[et al.].. Oxford ; New York: Oxford University Press; 2005. 
18. Barnato AE, McClellan MB, Kagay CR, Garber AM. Trends in inpatient treatment 
intensity among Medicare beneficiaries at the end of life. Health Serv Res. 
2004;39(2):363-375. doi:10.1111/j.1475-6773.2004.00232.x.
19. Cartwright A. Changes in life and care in the year before death 1969-1987. J Public 
Health Med. 1991;13(2):81-87.
20. Cassel EJ. The nature of suffering and the goals of medicine. N Engl J Med. 
1982;306(11):639-645. doi:10.1056/NEJM198203183061104.
21. Singer AE, Meeker D, Teno JM, Lynn J, Lunney JR, Lorenz KA. Symptom trends in 
the last year of life from 1998 to 2010: a cohort study. Ann Intern Med. 
2015;162(3):175-183. doi:10.7326/M13-1609.
22. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far 
advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and 
renal disease. J Pain Symptom Manage. 2006;31(1):58-69. 
doi:10.1016/j.jpainsymman.2005.06.007.
23. Connors Jr AF, Dawson NV, Desbiens NA, et al. A controlled trial to improve care for 
seriously ill hospitalized patients. JAMA J Am Med Assoc. 1995;274(20):1591-1598.
24. Clark D. Religion, medicine, and community in the early origins of St. Christopher’s 
Hospice. J Palliat Med. 2001;4(3):353-360.
25. Clark D. Originating a movement: Cicely Saunders and the development of St 
Christopher’s Hospice, 1957-1967. Mortality. 1998;3(1):43-63.
26. WHO Definition of Palliative Care. WHO. 
http://www.who.int/cancer/palliative/definition/en/. Accessed February 21, 2015.
27. National Tay-Sachs & Allied Diseases Association. NTSAD - Philosophy of Care. 
Philosophy of Care. http://www.ntsad.org/index.php/infantile-a-juvenile-
support/newly-diagnosed/philosophy-of-care. Published May 20, 2014. Accessed 
February 21, 2015.
28. Gary GA. Facing terminal illness in children with AIDS:  developing a philosophy of 
care for patients, families, and caregivers. Home Healthc Nurse. 1992;10(2):40-43.
128
29. Conant L, Lowney A. The role of hospice philosophy of care in nonhospice settings. J
Law Med Ethics. 1996;24(4):365.
30. National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines 
for Quality Palliative Care, 2nd ed. 2009.
31. Saunders C. A personal therapeutic journey. BMJ. 1996;313(7072):1599-1601.
32. Eues SK. End-of-life care: improving quality of life at the end of life. Prof Case 
Manag. 2007;12(6):339-344.
33. Rodriguez KL, Barnato AE, Arnold RM. Perceptions and utilization of palliative care 
services in acute care hospitals. J Palliat Med. 2007;10(1):99-110. 
doi:10.1089/jpm.2006.0155.
34. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare and Medicaid 
programs: Hospice Conditions of Participation; Final rule. Fed Regist. 
2008;73(109):32087-32220.
35. Centers for Medicare and Medicaid Services. Medicare Hospice Benefit. January 
2013.
36. Sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health 
Organization’s global perspective. J Pain Symptom Manage. 2002;24(2):91-96.
37. Chamberlain BH. What’s in a name? Am J Hosp Palliat Med. 2001;18(6):367-369. 
doi:10.1177/104990910101800602.
38. Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. Simultaneous 
care: a model approach to the perceived conflict between investigational therapy and 
palliative care. J Pain Symptom Manage. 2004;28(6):548-556. 
doi:10.1016/j.jpainsymman.2004.03.002.
39. Meyers FJ, Linder J. Simultaneous care: disease treatment and palliative care 
throughout illness. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(7):1412-1415.
40. Philip JAM, Komesaroff P. Ideals and compromises in palliative care. J Palliat Med. 
2006;9(6):1339-1347. doi:10.1089/jpm.2006.9.1339.
41. Saunders C. The evolution of palliative care. Pharos Alpha Omega Alpha-Honor Med 
Soc Alpha Omega Alpha. 2003;66(3):4-7.
42. National Quality Forum. A National Framework and Preferred Practies for Hospice 
and Palliative care. 2006.
43. National Quality Forum (NQF). Policies and Tools for Hospice and Palliative Care 
Programs:  A Crosswalk of National Quality Forum Preferred Practices. 2007.
129
44. Meyer MJ. Integration of pain services into pediatric oncology. Int Anesthesiol Clin. 
2006;44(1):95-107.
45. Hui D, Nooruddin Z, Didwaniya N, et al. Concepts and definitions for “actively 
dying,” “end of life,” “terminally ill,” “terminal care,” and “transition of care”: a 
systematic review. J Pain Symptom Manage. 2014;47(1):77-89. 
doi:10.1016/j.jpainsymman.2013.02.021.
46. Raj PP. The 2009 John J. Bonica award lecture: the impact of managing pain in the 
practice of medicine through the ages. Reg Anesth Pain Med. 2010;35(4):378-385, 
377.
47. Hamilton GR, Baskett TF. In the arms of Morpheus: the development of morphine for 
postoperative pain relief. Can J Anaesth J Can Anesth. 2000;47(4):367-374. 
doi:10.1007/BF03020955.
48. Tallmadge GK. Some anesthetics of antiquity. J Hist Med Allied Sci. 1946;1(4):515-
520.
49. Dabbagh A, Elyasi H, Rajaei S. Anesthesia in ancient Iran. Anesth Analg. 
2010;111(2):584. doi:10.1213/ANE.0b013e3181e33174.
50. Brabazon J. Albert Schweitzer: A Biography. Syracuse University Press; 2000.
51. Clark D. From margins to centre: a review of the history of palliative care in cancer. 
Lancet Oncol. 2007;8(5):430-438.
52. Clark D. “Total pain,” disciplinary power and the body in the work of Cicely 
Saunders, 1958–1967. Soc Sci Med. 1999;49(6):727-736. doi:10.1016/S0277-
9536(99)00098-2.
53. Seymour J, Clark D, Winslow M. Pain and palliative care: the emergence of new 
specialties. J Pain Symptom Manage. 2005;29(1):2-13. 
doi:10.1016/j.jpainsymman.2004.08.008.
54. Singer PA, Martin DK, Kelner M. Quality end-of-life care: patients’ perspectives. 
JAMA J Am Med Assoc. 1999;281(2):163-168.
55. Teno JM, Mor V, Ward N, et al. Bereaved family member perceptions of quality of 
end-of-life care in U.S. regions with high and low usage of intensive care unit care. J 
Am Geriatr Soc. 2005;53(11):1905-1911. doi:10.1111/j.1532-5415.2005.53563.x.
56. Emanuel EJ, Emanuel LL. The promise of a good death. Lancet. 1998;351 Suppl 
2:SII21-SII29.
57. Institute of Medicine (US) Committee on Care at the End of Life. Approaching 
Death: Improving Care at the End of Life. (Field MJ, Cassel CK, eds.). Washington 
(DC): National Academies Press (US); 1997. 
http://www.ncbi.nlm.nih.gov/books/NBK233605/. Accessed February 4, 2015.
130
58. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA. 
Factors considered important at the end of life by patients, family, physicians, and 
other care providers. JAMA J Am Med Assoc. 2000;284(19):2476-2482.
59. Vig EK, Davenport NA, Pearlman RA. Good deaths, bad deaths, and preferences for 
the end of life: a qualitative study of geriatric outpatients. J Am Geriatr Soc. 
2002;50(9):1541-1548.
60. Smith AK, Cenzer IS, Knight SJ, et al. The epidemiology of pain during the last 2 
years of life. Ann Intern Med. 2010;153(9):563-569. doi:10.7326/0003-4819-153-9-
201011020-00005.
61. Semionov V, Singer Y, Shvartzman P. Prevalence and management of symptoms 
during the last month of life. Isr Med Assoc J IMAJ. 2012;14(2):96-99.
62. Definition of Analgesia. http://www.merriam-webster.com/dictionary/analgesia. 
Accessed February 25, 2015.
63. Moryl N, Coyle N, Foley KM. Managing an acute pain crisis in a patient with 
advanced cancer: “this is as much of a crisis as a code.” JAMA. 2008;299(12):1457-
1467. doi:10.1001/jama.299.12.1457.
64. Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ. Understanding the experience of
pain in terminally ill patients. Lancet. 2001;357(9265):1311-1315. 
doi:10.1016/S0140-6736(00)04515-3.
65. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van 
Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of 
the past 40 years. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2007;18(9):1437-1449.
doi:10.1093/annonc/mdm056.
66. Paice JA, Toy C, Shott S. Barriers to cancer pain relief: fear of tolerance and 
addiction. J Pain Symptom Manage. 1998;16(1):1-9.
67. Desandre PL, Quest TE. Management of cancer-related pain. Emerg Med Clin North 
Am. 2009;27(2):179-194. doi:10.1016/j.emc.2009.01.002.
68. McCarberg BH. The treatment of breakthrough pain. Pain Med Malden Mass. 2007;8 
Suppl 1:S8-S13. doi:10.1111/j.1526-4637.2006.00270.x.
69. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and 
characteristics. Pain. 1990;41(3):273-281.
70. Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S. Assessment and 
classification of cancer breakthrough pain: a systematic literature review. Pain. 
2010;149(3):476-482. doi:10.1016/j.pain.2010.02.035.
131
71. National Hospice and Palliative Care Organization. Patient Outcomes and Measures: 
Comfortable Dying Measure (NQF # 0209 ). ProtocolsOCFMeasures.PDF - 
Comfortable_Dying_Manual.pdf. 
http://www.nhpco.org/sites/default/files/public/Statistics_Research/Comfortable_Dyin
g_Manual.pdf. Accessed April 29, 2015.
72. Kelly L, Bender L, Harris P, Casarett D. The “comfortable dying” measure: how 
patient characteristics affect hospice pain management quality scores. J Palliat Med. 
2014;17(6):721-724. doi:10.1089/jpm.2013.0571.
73. Twaddle ML, Maxwell TL, Cassel JB, et al. Palliative care benchmarks from 
academic medical centers. J Palliat Med. 2007;10(1):86-98. 
doi:10.1089/jpm.2006.0048.
74. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of 
cancer pain: a survey of strategies used by pain physicians for the selection of 
analgesic drugs and routes of administration. Cancer. 1995;76(7):1283-1293.
75. Rhodin A. The rise of opiophobia: is history a barrier to prescribing? J Pain Palliat 
Care Pharmacother. 2006;20(3):31-32.
76. Musto DF. Opium, cocaine and marijuana in American history. Sci Am. 
1991;265(1):40-47.
77. Dews TE, Mekhail N. Safe use of opioids in chronic noncancer pain. Cleve Clin J 
Med. 2004;71(11):897-904.
78. Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Can Fam Physician. 
2010;56(6):514-517.
79. Raffa RB, Pergolizzi JV. A modern analgesics pain “pyramid.” J Clin Pharm Ther. 
2014;39(1):4-6. doi:10.1111/jcpt.12110.
80. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health 
Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 
1995;63(1):65-76.
81. Leung L. From ladder to platform: a new concept for pain management. J Prim 
Health Care. 2012;4(3):254-258.
82. Chung KC, Barlev A, Braun AH, Qian Y, Zagari M. Assessing analgesic use in 
patients with advanced cancer: development of a new scale--the Analgesic 
Quantification Algorithm. Pain Med Malden Mass. 2014;15(2):225-232. 
doi:10.1111/pme.12299.
83. Bell K, Salmon A. Pain, physical dependence and pseudoaddiction: redefining 
addiction for “nice” people? Int J Drug Policy. 2009;20(2):170-178. 
doi:10.1016/j.drugpo.2008.06.002.
132
84. Covington EC. Opiophobia, opiophilia, opioagnosia. Pain Med Malden Mass. 
2000;1(3):217-223.
85. Weinstein SM, Laux LF, Thornby JI, et al. Physicians’ attitudes toward pain and the 
use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. 
South Med J. 2000;93(5):479-487.
86. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 
2007;10(3):479-491.
87. Harden RN. Chronic pain and opiates: a call for moderation. Arch Phys Med Rehabil. 
2008;89(3 Suppl 1):S72-S76. doi:10.1016/j.apmr.2007.12.013.
88. Gallagher RM, Rosenthal LJ. Chronic pain and opiates: balancing pain control and 
risks in long-term opioid treatment. Arch Phys Med Rehabil. 2008;89(3 Suppl 1):S77-
S82. doi:10.1016/j.apmr.2007.12.003.
89. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of 
oral morphine: an evidence-based report. J Clin Oncol Off J Am Soc Clin Oncol. 
2001;19(9):2542-2554.
90. Cherny NI. The pharmacologic management of cancer pain. Oncol Williston Park N. 
2004;18(12):1499-1515; discussion 1516, 1520-1521, 1522, 1524.
91. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients:
a systematic review and literature synthesis. Clin J Pain. 2008;24(6):497-508. 
doi:10.1097/AJP.0b013e31816b1070.
92. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. 
Eur J Pain Lond Engl. 2007;11(5):490-518. doi:10.1016/j.ejpain.2006.08.004.
93. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 
1980;302(2):123.
94. Passik SD, Kirsh KL, McDonald MV, et al. A pilot survey of aberrant drug-taking 
attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom 
Manage. 2000;19(4):274-286.
95. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A long-term survey of 
morphine in cancer pain patients. J Pain Symptom Manage. 1992;7(5):259-266.
96. Graves DA, Foster TS, Batenhorst RL, Bennett RL, Baumann TJ. Patient-controlled 
analgesia. Ann Intern Med. 1983;99(3):360-366.
97. Etches RC. Patient-controlled analgesia. Surg Clin North Am. 1999;79(2):297-312.
98. Baumrucker SJ, Carter GT, VandeKieft G, et al. Diversion of opioid pain medications 
at end-of-life. Am J Hosp Palliat Care. 2009;26(3):214-218. 
doi:10.1177/1049909109336005.
133
99. Childers JW, Arnold RM. “I feel uncomfortable ‘calling a patient out’”: educational 
needs of palliative medicine fellows in managing opioid misuse. J Pain Symptom 
Manage. 2012;43(2):253-260. doi:10.1016/j.jpainsymman.2011.03.009.
100. Hicks RW, Sikirica V, Nelson W, Schein JR, Cousins DD. Medication errors involving
patient-controlled analgesia. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst
Pharm. 2008;65(5):429-440. doi:10.2146/ajhp070194.
101. Macintyre PE. Intravenous patient-controlled analgesia: one size does not fit all. 
Anesthesiol Clin N Am. 2005;23(1):109-123. doi:10.1016/j.atc.2004.11.002.
102. Dalal S, Bruera E. Assessment and management of Pain in the terminally ill. Prim 
Care Clin Off Pract. 2011;38(2):195-223, vii - viii. doi:10.1016/j.pop.2011.03.004.
103. Vockley M. Silent danger: opioids, PCA pumps, and the case for continuous 
monitoring. Biomed Instrum Technol Assoc Adv Med Instrum. 2013;47(6):454-465. 
doi:10.2345/0899-8205-47.6.454.
104. Macintyre PE, Loadsman JA, Scott DA. Opioids, ventilation and acute pain 
management. Anaesth Intensive Care. 2011;39(4):545-558.
105. Etches RC. Respiratory depression associated with patient-controlled analgesia: a 
review of eight cases. Can J Anaesth J Can Anesth. 1994;41(2):125-132. 
doi:10.1007/BF03009805.
106. Grass JA. Patient-controlled analgesia. Anesth Analg. 2005;101(5 Suppl):S44-S61.
107. Whitecar PS, Jonas AP, Clasen ME. Managing pain in the dying patient. Am Fam 
Physician. 2000;61(3):755-764.
108. Portenoy RK, Sibirceva U, Smout R, et al. Opioid use and survival at the end of life: a
survey of a hospice population. J Pain Symptom Manage. 2006;32(6):532-540. 
doi:10.1016/j.jpainsymman.2006.08.003.
109. Bercovitch M, Waller A, Adunsky A. High dose morphine use in the hospice setting. A
database survey of patient characteristics and effect on life expectancy. Cancer. 
1999;86(5):871-877.
110. Bercovitch M, Adunsky A. Patterns of high-dose morphine use in a home-care hospice
service: should we be afraid of it? Cancer. 2004;101(6):1473-1477. 
doi:10.1002/cncr.20485.
111. Thorns A, Sykes N. Opioid use in last week of life and implications for end-of-life 
decision-making. Lancet. 2000;356(9227):398-399. doi:10.1016/S0140-
6736(00)02534-4.
112. Portenoy R. Drug therapy for cancer pain. Am J Hosp Palliat Care. 1990;7(6):10-19.
134
113. Khan MIA, Walsh D, Brito-Dellan N. Opioid and adjuvant analgesics: compared and 
contrasted. Am J Hosp Palliat Care. 2011;28(5):378-383. 
doi:10.1177/1049909111410298.
114. Cherny NI. Opioids and the management of cancer pain. Eur J Cancer Suppl. 
2005;3(3):61-75. doi:10.1016/S1359-6349(05)80263-0.
115. Storey P, Knight CF, Schonwetter RS. Pocket Guide to Hospice/Palliative Medicine. 
American Academy of Hospice and Palliative Care; 2003.
116. Pujol L, Katz N, Zacharoff K. The PainEdu.org Manual. Inflexxion; 2007.
117. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of 
severe cancer pain. Palliat Med. 2003;17(3):248-256.
118. Caraceni A, Martini C, Zecca E, Fagnoni E. Cancer pain management and palliative 
care. Handb Clin Neurol. 2012;104:391-415. doi:10.1016/B978-0-444-52138-
5.00027-X.
119. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of 
cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 
2012;13(2):e58-e68. doi:10.1016/S1470-2045(12)70040-2.
120. Cleary JF. The Pharmacologic Management of Cancer Pain. J Palliat Med. 
2007;10(6):1369-1394. doi:10.1089/jpm.2007.9842.
121. Harris DG. Management of pain in advanced disease. Br Med Bull. 2014;110(1):117-
128. doi:10.1093/bmb/ldu010.
122. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. J Palliat 
Med. 2006;9(4):977-992. doi:10.1089/jpm.2006.9.977.
123. Moote CA. The prevention of postoperative pain. Can J Anaesth J Can Anesth. 
1994;41(6):527-533. doi:10.1007/BF03011550.
124. Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: 
pharmacological, experimental, clinical and economical perspectives. Br J Clin 
Pharmacol. 2013;75(1):60-78. doi:10.1111/j.1365-2125.2012.04317.x.
125. Opioid painkillers summarized - Consumer Reports Health - Opioids-2pager-FINAL-
June2008.pdf. https://www.consumerreports.org/health/resources/pdf/best-buy-
drugs/Opioids-2pager-FINAL-June2008.pdf. Accessed May 27, 2015.
126. Pergolizzi JV, Taylor R, Muniz E. The role of patient-controlled analgesia in the 
management of chronic pain. Eur J Pain Suppl. 2011;5(2). 
doi:10.1016/j.eujps.2011.08.046.
135
127. Wilson WC, Smedira NG, Fink C, McDowell JA, Luce JM. Ordering and 
administration of sedatives and analgesics during the withholding and withdrawal of 
life support from critically ill patients. JAMA. 1992;267(7):949-953.
128. Sykes NP. Morphine kills the pain, not the patient. The Lancet. 2007;369(9570):1325-
1326. doi:10.1016/S0140-6736(07)60611-4.
129. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol. 
2003;4(5):312-318. doi:10.1016/S1470-2045(03)01079-9.
130. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on
survival in terminally ill cancer patients. J Pain Symptom Manage. 2001;21(4):282-
289. doi:10.1016/S0885-3924(01)00258-5.
131. Ripamonti C, Bandieri E. Pain therapy. Crit Rev Oncol Hematol. 2009;70(2):145-159. 
doi:10.1016/j.critrevonc.2008.12.005.
132. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353(9165):1695-
1700. doi:10.1016/S0140-6736(99)01310-0.
133. Sessle BJ. The pain crisis: what it is and what can be done. Pain Res Treat. 
2012;2012:1-6. doi:10.1155/2012/703947.
134. Riley JL, Hastie BA. Individual differences in opioid efficacy for chronic noncancer 
pain. Clin J Pain. 2008;24(6):509-520. doi:10.1097/AJP.0b013e31816c6654.
135. Smith HS. Variations in opioid responsiveness. Pain Physician. 2008;11(2):237-248.
136. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response
to different opioids: report of five cases. Pain. 1992;49(1):87-91.
137. Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236-2247. 
doi:10.1016/S0140-6736(11)60236-5.
138. Mather LE. Pharmacokinetics and patient-controlled analgesia. Acta Anaesthesiol 
Belg. 1992;43(1):5-20.
139. Woodhouse A, Mather LE. The minimum effective concentration of opioids: a 
revisitation with patient controlled analgesia fentanyl. Reg Anesth Pain Med. 
2000;25(3):259-267.
140. Woodhouse A, Ward ME, Mather LE. Intra-subject variability in post-operative 
patient-controlled analgesia (PCA): is the patient equally satisfied with morphine, 
pethidine and fentanyl? Pain. 1999;80(3):545-553.
141. Stamer UM, Grond S, Maier C. Responders and non-responders to post-operative pain
treatment: the loading dose predicts analgesic needs. Eur J Anaesthesiol. 
1999;16(2):103-110.
136
142. Carr DB, Reines HD, Schaffer J, Polomano RC, Lande S. The impact of technology 
on the analgesic gap and quality of acute pain management. Reg Anesth Pain Med. 
2005;30(3):286-291.
143. Polomano RC, Rathmell JP, Krenzischek DA, Dunwoody CJ. Emerging trends and 
new approaches to acute pain management. J Perianesth Nurs. 2008;23(1, 
Supplement):S43-S53. doi:10.1016/j.jopan.2007.11.006.
144. Sechzer PH. Patient-controlled analgesia (PCA): a retrospective. Anesthesiology. 
1990;72(4):735-736.
145. Sechzer PH. Studies in pain with the analgesic-demand system. Anesth Analg. 
1971;50(1):1-10.
146. Sechzer P. Objective measurement of pain. Anesthesiology. 1968;29(1):209-210.
147. Forrest WH, Smethurst PW, Kienitz ME. Self-administration of intravenous 
analgesics. Anesthesiology. 1970;33(3):363-365.
148. White PF. Use of patient-controlled analgesia for management of acute pain. JAMA. 
1988;259(2):243-247.
149. Keeri-Szanto M. Apparatus for demand analgesia. Can Anaesth Soc J. 
1971;18(5):581-582. doi:10.1007/BF03026023.
150. Rosen M, Kirby A. The genesis, development, and current usage of patient controlled 
analgesia (PCA): An anniversary. Anesth News. 2009;(267):9-11.
151. Keeri-Szanto M. Patient-controlled analgesia. Can Anaesth Soc J. 1984;31(1):121-
122. doi:10.1007/BF03011501.
152. Bast C, Hayes P. Patient-controlled analgesia. Nursing (Lond). 1986;16(1):25.
153. Swanson G, Smith J, Bulich R, New P, Shiffman R. Patient-controlled analgesia for 
chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Oncol. 
1989;7(12):1903-1908.
154. Citron ML, Johnston-Early A, Boyer M, Krasnow SH, Hood M, Cohen MH. Patient-
controlled analgesia for severe cancer pain. Arch Intern Med. 1986;146(4). 
doi:10.1001/archinte.146.4.734.
155. Kerr IG, Sone M, Deangelis C, Iscoe N, MacKenzie R, Schueller T. Continuous 
narcotic infusion with patient-controlled analgesia for chronic cancer pain in 
outpatients. Ann Intern Med. 1988;108(4):554-557.
156. Walsh TD, Smyth EM, Currie K, Glare PA, Schneider J. A pilot study, review of the 
literature, and dosing guidelines for patient-controlled analgesia using subcutaneous 
morphine sulphate for chronic cancer pain. Palliat Med. 1992;6(3):217-226. 
doi:10.1177/026921639200600306.
137
157. Baumann TJ, Batenhorst RL, Graves DA, Foster TS, Bennett RL. Patient-controlled 
analgesia in the terminally ill cancer patient. Drug Intell Clin Pharm. 1986;20(4):297-
301.
158. Harrison P. Intravenous-subcutaneous patient-controlled analgesia for cancer pain 
management. Tech Reg Anesth Pain Manag. 1997;1(1):47-52. doi:10.1016/S1084-
208X(06)80010-8.
159. Lehmann KA. Recent developments in patient-controlled analgesia. J Pain Symptom 
Manage. 2005;29(5 Suppl):S72-S89. doi:10.1016/j.jpainsymman.2005.01.005.
160. Schiessl C, Sittl R, Griessinger N, Lutter N, Schuettler J. Intravenous morphine 
consumption in outpatients with cancer during their last week of life--an analysis 
based on patient-controlled analgesia data. Support Care Cancer Off J Multinatl Assoc
Support Care Cancer. 2008;16(8):917-923. doi:10.1007/s00520-007-0352-6.
161. Ferrell BR, Nash CC, Warfield C. The role of patient-controlled analgesia in the 
management of cancer pain. J Pain Symptom Manage. 1992;7(3):149-154.
162. Schiessl C, Schestag I, Sittl R, Drake R, Zernikow B. Rhythmic pattern of PCA opioid
demand in adults with cancer pain. Eur J Pain Lond Engl. 2010;14(4):372-379. 
doi:10.1016/j.ejpain.2009.06.009.
163. Pasero C, McCaffery M. Authorized and unauthorized use of PCA pumps: clarifying 
the use of patient-controlled analgesia, in light of recent alerts. Am J Nurs. 
2005;105(7):30-31, 33.
164. Paul JE, Bertram B, Antoni K, et al. Impact of a comprehensive safety initiative on 
patient-controlled analgesia errors. Anesthesiology. 2010;113(6):1427-1432. 
doi:10.1097/ALN.0b013e3181fcb427.
165. Schein JR, Hicks RW, Nelson WW, Sikirica V, Doyle DJ. Patient-controlled analgesia-
related medication errors in the postoperative period: causes and prevention. Drug Saf
Int J Med Toxicol Drug Exp. 2009;32(7):549-559.
166. Syed S, Paul JE, Hueftlein M, Kampf M, McLean RF. Morphine overdose from error 
propagation on an acute pain service. Can J Anaesth J Can Anesth. 2006;53(6):586-
590. doi:10.1007/BF03021849.
167. Hankin CS, Schein J, Clark JA, Panchal S. Adverse events involving intravenous 
patient-controlled analgesia. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst
Pharm. 2007;64(14):1492-1499. doi:10.2146/ajhp060220.
168. NCCN. NCCN clinical Practice Guidelines in Oncology: Adult Cancer Pain. January 
2014.
169. Gilron I. Analgesia controlled with patience: towards a better understanding of 
analgesic self-administration behaviour. Can J Anaesth J Can Anesth. 2008;55(2):75-
81. doi:10.1007/BF03016318.
138
170. Prewitt J, Schneider S, Horvath M, Hammond J, Jackson J, Ginsberg B. PCA safety 
data review after clinical decision support and smart pump technology 
implementation. J Patient Saf. 2013;9(2):103-109. 
doi:10.1097/PTS.0b013e318281b866.
171. Burgess DJ. Are providers more likely to contribute to healthcare disparities under 
high levels of cognitive load? How features of the healthcare setting may lead to 
biases in medical decision making. Med Decis Mak Int J Soc Med Decis Mak. 
2010;30(2):246-257. doi:10.1177/0272989X09341751.
172. Weir CR, Nebeker JJR, Hicken BL, Campo R, Drews F, LeBar B. A Cognitive Task 
Analysis of information management strategies in a computerized provider order entry
environment. J Am Med Inform Assoc. 2007;14(1):65-75. doi:10.1197/jamia.M2231.
173. Glasspool DW, Oettinger A, Smith-Spark JH, Castillo FD, Monaghan VEL, Fox J. 
Supporting medical planning by mitigating cognitive load. Methods Inf Med. 
2007;46(6):636-640.
174. Rogers RD, Monsell S. Costs of a predictible switch between simple cognitive tasks. J
Exp Psychol Gen. 1995;124(2):207-231. doi:10.1037/0096-3445.124.2.207.
175. McDonald CJ. Protocol based computer reminders, the quality of care and the non 
perfectability of man. N Engl J Med. 1976;295(24):1351-1355. 
doi:10.1056/NEJM197612092952405.
176. Cartwright J, de Sylva S, Glasgow M, Rivard R, Whiting J. Inaccessible information 
is useless information - addressing the knowledge gap. J Med Pract Manage. 
2002;18(1):36-41.
177. Smith PC, Araya-Guerra R, Bublitz C, et al. Missing clinical information during 
primary care visits. JAMA. 2005;293(5):565-571. doi:10.1001/jama.293.5.565.
178. Gorman PN, Helfand M. Information seeking in primary care: how physicians choose 
which clinical questions to pursue and which to leave unanswered. Med Decis 
Making. 1995;15(2):113-119. doi:10.1177/0272989X9501500203.
179. Maviglia SM, Zielstorff RD, Paterno M, Teich JM, Bates DW, Kuperman GJ. 
Automating complex guidelines for chronic disease: lessons learned. J Am Med 
Inform Assoc JAMIA. 2003;10(2):154-165.
180. Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval 
from electronic health records: A report of University of Michigan’s nine-year 
experience in developing and using the Electronic Medical Record Search Engine 
(EMERSE). J Biomed Inform. May 2015. doi:10.1016/j.jbi.2015.05.003.
181. Haug PJ, Gardner RM, Tate KE, et al. Decision support in medicine: examples from 
the HELP system. Comput Biomed Res Int J. 1994;27(5):396-418.
139
182. Section 4 - Types of CDS Interventions | AHRQ National Resource Center; Health 
Information Technology: Best Practices Transforming Quality, Safety, and Efficiency. 
http://healthit.ahrq.gov/ahrq-funded-projects/clinical-decision-support-
initiative/chapter-1-approaching-clinical-decision/section-4-types-cds-interventions. 
Accessed May 29, 2015.
183. Wright A, Sittig DF, Ash JS, et al. Development and evaluation of a comprehensive 
clinical decision support taxonomy: comparison of front-end tools in commercial and 
internally developed electronic health record systems. J Am Med Inform Assoc JAMIA.
2011;18(3):232-242. doi:10.1136/amiajnl-2011-000113.
184. Justin D. Clutter MD, Leslie Lenert MD MS. Towards interoperable standards for late 
life care preferences (POSTER). November 2013.
185. Vanderveen T. From Smart Pumps to Intelligent Infusion Systems – The Promise of 
Interoperability. Patient Safety & Quality Healthcare. http://psqh.com/may-june-
2014/from-smart-pumps-to-intelligent-infusion-systems-the-promise-of-
interoperability. Published June 2014. Accessed June 2, 2015.
186. Perna G. KLAS: EMR/Smart Pump Integration is the Future. Healthcare Informatics. 
http://www.healthcare-informatics.com/news-item/klas-emrsmart-pump-integration-
future. Published August 1, 2013. Accessed June 2, 2015.
187. Vecchione A. Smart Pumps Play Catch Up With EMRs - InformationWeek. 
InformationWeek Healthcare. http://www.informationweek.com/healthcare/electronic-
health-records/smart-pumps-play-catch-up-with-emrs/d/d-id/1104260? Published May
8, 2012. Accessed June 2, 2015.
188. Smart Pumps | September 2008 Newsletter. KLAS Online. 
http://www.klasresearch.com/news/newsletters/2008-09/sp2008.aspx. Published 
September 2008. Accessed June 2, 2015.
189. Ash JS, Berg M, Coiera E. Some unintended consequences of information technology 
in health care: the nature of patient care information system-related errors. J Am Med 
Inform Assoc JAMIA. 2004;11(2):104-112. doi:10.1197/jamia.M1471.
190. Vaughan D. The dark side of organizations: mistake, misconduct and disaster. Annu 
Rev Sociol. 1999;25:271.
191. Pidgeon N, O’Leary M. Man-made disasters: why technology and organizations 
(sometimes) fail. Saf Sci. 2000;34(1–3):15-30. doi:10.1016/S0925-7535(00)00004-7.
192. Reason J. Human Error: Models and Management. BMJ. 2000;320(7237):768-770.
193. Institute of Medicine (US) Committee on Quality of Health Care in America. To Err 
Is Human: Building a Safer Health System. (Kohn LT, Corrigan JM, Donaldson MS, 
eds.). Washington (DC): National Academies Press (US); 2000. 
http://www.ncbi.nlm.nih.gov/books/NBK225182/. Accessed February 7, 2015.
140
194. Sittig DF, Wright A, Osheroff JA, et al. Grand challenges in clinical decision support. 
J Biomed Inform. 2008;41(2):387-392. doi:10.1016/j.jbi.2007.09.003.
195. Kawamoto K, Del Fiol G, Lobach DF, Jenders RA. Standards for scalable clinical 
decision support: need, current and emerging standards, gaps, and proposal for 
progress. Open Med Inform J. 2010;4:235.
196. Bates DW, Kuperman GJ, Wang S, et al. Ten commandments for effective clinical 
decision support: making the practice of evidence-based medicine a reality. J Am Med 
Inform Assoc JAMIA. 2003;10(6):523-530. doi:10.1197/jamia.M1370.
197. Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A, Detmer DE. A Roadmap 
for National Action on Clinical Decision Support. J Am Med Inform Assoc. 
2007;14(2):141-145. doi:10.1197/jamia.M2334.
198. Davies M. Concept mapping, mind mapping and argument mapping: what are the 
differences and do they matter? High Educ. 2010;62(3):279-301. doi:10.1007/s10734-
010-9387-6.
199. Brinkmann A. Graphical Knowledge Display – Mind Mapping and Concept Mapping 
as Efficient Tools in Mathematics Education. Math Educ Revie W. 2003;(16):35-48.
200. ScanTailor. http://scantailor.org/. Accessed April 24, 2015.
201. Writer | LibreOffice - Free Office Suite - Fun Project - Fantastic People. 
https://www.libreoffice.org/discover/writer/. Accessed April 24, 2015.
202. Ghostscript: Ghostscript. http://www.ghostscript.com/. Accessed April 24, 2015.
203. ImageMagick: Convert, Edit, Or Compose Bitmap Images. 
http://www.imagemagick.org/. Accessed April 24, 2015.
204. Tracker Software Products: Product. http://www.tracker-software.com/product/pdf-
xchange-viewer. Accessed April 24, 2015.
205. FTPServer - Android Apps on Google Play. https://play.google.com/store/apps/details?
id=lutey.FTPServer&hl=en. Accessed April 28, 2015.
206. FileZilla - The free FTP solution. https://filezilla-project.org/. Accessed April 28, 
2015.
207. Dropsync (Dropbox Autosync) - Android Apps on Google Play. 
https://play.google.com/store/apps/details?id=com.ttxapps.dropsync&hl=en. Accessed 
April 28, 2015.
208. Dropbox. https://www.dropbox.com/. Accessed May 27, 2015.
209. RepliGo Reader [now Discontinued]. http://m.cerience.com/reader/. Accessed May 
27, 2015.
141
210. ezPDF Reader - Multimedia PDF - Android Apps on Google Play. 
https://play.google.com/store/apps/details?id=udk.android.reader&hl=en. Accessed 
April 28, 2015.
211. Docear. Docear. http://www.docear.org/. Accessed April 18, 2015.
212. Mind Map - definition of Mind Map by The Free Dictionary. 
http://www.thefreedictionary.com/mind+map. Accessed April 24, 2015.
213. Concept map - encyclopedia article about Concept map. 
http://encyclopedia.thefreedictionary.com/concept+map. Accessed April 24, 2015.
214. Data model - encyclopedia article about Data model. 
http://encyclopedia.thefreedictionary.com/data+model. Accessed April 24, 2015.
215. Alper BS, Hand JA, Elliott SG, et al. How much effort is needed to keep up with the 
literature relevant for primary care? J Med Libr Assoc JMLA. 2004;92(4):429-437.
216. Isaacs D, Fitzgerald D. Seven alternatives to evidence based medicine. BMJ. 
1999;319(7225):1618.
217. Tattersall C, Powell J, Stroud J, Pringle J. Mind mapping in qualitative research. Nurs 
Times. 2011;107(18):20-22.
218. Burgess-Allen J, Owen-Smith V. Using mind mapping techniques for rapid qualitative
data analysis in public participation processes. Health Expect. 2010;13(4):406-415. 
doi:10.1111/j.1369-7625.2010.00594.x.
219. Adams AS, Soumerai SB, Lomas J, Ross-Degnan D. Evidence of self-report bias in 
assessing adherence to guidelines. Int J Qual Health Care. 1999;11(3):187-192. 
doi:10.1093/intqhc/11.3.187.
220. Rosser WW, Palmer WH. Dissemination of guidelines on cholesterol. Effect on 
patterns of practice of general practitioners and family physicians in Ontario. Ontario 
Task Force on the Use and Provision of Medical Services. Can Fam Physician 
Médecin Fam Can. 1993;39:280-284.
221. Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice 
guidelines?: A framework for improvement. JAMA. 1999;282(15):1458-1465. 
doi:10.1001/jama.282.15.1458.
222. Brindis RG, Sennett C. Physician adherence to clinical practice guidelines: Does it 
really matter? Am Heart J. 2003;145(1):13-15. doi:10.1067/mhj.2003.25.
223. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do 
practice guidelines guide practice? The effect of a consensus statement on the practice 
of physicians. N Engl J Med. 1989;321(19):1306-1311.
142
224. Parker D, Lawton R. Judging the use of clinical protocols by fellow professionals. Soc
Sci Med. 2000;51(5):669-677. doi:10.1016/S0277-9536(00)00013-7.
225. McKinlay J, Link C, Freund K, Marceau L, O’Donnell A, Lutfey K. Sources of 
variation in physician adherence with clinical guidelines: results from a factorial 
experiment. J Gen Intern Med. 2007;22(3):289-296. doi:10.1007/s11606-006-0075-2.
226. Portney LG, Watkins MP. Foundations of Clinical Research: Applications to Practice.
3rd ed. Upper Saddle River, New Jersey: Pearson Education; 2009.
227. Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract 
Assess Res Eval. 2007;12(10):1-8.
228. Skulmoski G, Hartman F, Krahn J, Skulmoski G, Hartman F, Krahn J. The Delphi 
Method for graduate research. J Inf Technol Educ Res. 2007;6(1):1-21.
229. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic 
data capture (REDCap)--a metadata-driven methodology and workflow process for 
providing translational research informatics support. J Biomed Inform. 
2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010.
230. Sclove SL. Notes on Likert Scales. 
http://www.uic.edu/classes/idsc/ids270sls/likert.htm. Accessed June 13, 2015.
231. Norman G. Likert scales, levels of measurement and the “laws” of statistics. Adv 
Health Sci Educ. 2010;15(5):625-632.
232. Fleiss JL, Cohen J. The equivalence of Weighted Kappa and the Intraclass Correlation 
Coefficient as measures of reliability. Educ Psychol Meas. 1973;33(3):613-619. 
doi:10.1177/001316447303300309.
233. Mchugh ML. Interrater reliability: the kappa statistic. Biochem Medica. 
2012;22(3):276-282.
234. Müller R, Büttner P. A critical discussion of intraclass correlation coefficients. Stat 
Med. 1994;13(23-24):2465-2476.
235. Eppler MJ. A comparison between concept maps, mind maps, conceptual diagrams, 
and visual metaphors as complementary tools for knowledge construction and sharing.
Inf Vis. 2006;5(3):202-210. doi:10.1057/palgrave.ivs.9500131.
236. Mahmud I, Veneziano V. Mind-mapping: An effective technique to facilitate 
requirements engineering in agile software development. In: 2011 14th International 
Conference on Computer and Information Technology (ICCIT). ; 2011:157-162. 
doi:10.1109/ICCITechn.2011.6164775.
237. Jackson KM, Trochim WMK. Concept mapping as an alternative approach for the 
analysis of open-ended survey responses. Organ Res Methods. 2002;5(4):307-336. 
doi:10.1177/109442802237114.
143
238. Hey J. The Data, Information, Knowledge, Wisdom Chain: The Metaphorical Link. 
2004. http://www.dataschemata.com/uploads/7/4/8/7/7487334/dikwchain.pdf. 
Accessed November 19, 2015.
239. DIKW Pyramid. In: Wikipedia, the Free Encyclopedia. ; 2015. 
https://en.wikipedia.org/w/index.php?title=DIKW_Pyramid&oldid=690798425. 
Accessed November 19, 2015.
240. Graves JR, Corcoran-Perry S. The study of nursing informatics. Holist Nurs Pract. 
1996;11(1):15-24.
241. Matney S, Brewster PJ, Sward KA, Cloyes KG, Staggers N. Philosophical approaches
to the nursing informatics data-information-knowledge-wisdom framework. Adv Nurs 
Sci. 2011;34(1):6-18.
242. Hallgren KA. Computing Inter-Rater Reliability for observational data: an overview 
and tutorial. Tutor Quant Methods Psychol. 2012;8(1):23-34.
243. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 
1993;46(5):423-429.
244. Condition - FHIR v0.0.82. http://www.hl7.org/fhir/condition.html. Accessed June 1, 
2015.
245. Del Fiol G, Crouch BI, Cummins MR. Data standards to support health information 
exchange between poison control centers and emergency departments. J Am Med 
Inform Assoc JAMIA. October 2014. doi:10.1136/amiajnl-2014-003127.
246. D’Amore JD, Mandel JC, Kreda DA, et al. Are Meaningful Use Stage 2 certified 
EHRs ready for interoperability? Findings from the SMART C-CDA Collaborative. J 
Am Med Inform Assoc JAMIA. 2014;21(6):1060-1068. doi:10.1136/amiajnl-2014-
002883.
247. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of 
the WHO method for cancer pain relief. Cancer. 1987;59(4):850-856.
248. Walker VA, Hoskin PJ, Hanks GW, White ID. Evaluation of WHO analgesic 
guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom 
Manage. 1988;3(3):145-149.
249. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain.  Clinical Practice 
Guideline No. 9. Rockville, MD: Agency for Health Care Policy and Research, US 
Department of Health and Human Services, Public Health Service; 1994.
250. Mercadante S. Pain treatment and outcomes for patients with advanced cancer who 
receive follow-up care at home. Cancer. 1999;85(8):1849-1858.
251. Schug SA, Zech D, Dörr U. Cancer pain management according to WHO analgesic 
guidelines. J Pain Symptom Manage. 1990;5(1):27-32.
144
252. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA. Validation of World Health 
Organization guidelines for cancer pain relief during the last days and hours of life. J 
Pain Symptom Manage. 1991;6(7):411-422.
